naltrexone has been researched along with buprenorphine in 453 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (4.42) | 18.7374 |
| 1990's | 35 (7.73) | 18.2507 |
| 2000's | 71 (15.67) | 29.6817 |
| 2010's | 166 (36.64) | 24.3611 |
| 2020's | 161 (35.54) | 2.80 |
| Authors | Studies |
|---|---|
| Adapa, ID; Auh, JS; Berzetei-Gurske, IP; Brandt, SR; Craymer, K; Farrington, L; Haggart, D; Kennedy, JM; O'Brien, A; Polgar, WE; Rodriguez, L; Schwartz, RW; Toll, L; White, A | 1 |
| Masukawa, Y; Misawa, M; Nagase, H; Shiozaki, Y; Suzuki, T | 1 |
| Doty, P; Dykstra, LA; Johnson, AB; Picker, MJ | 1 |
| Kleber, HD; Kosten, TR; Morgan, C | 3 |
| Mello, NK; Mendelson, JH | 3 |
| Goldberg, SR; Grayson, NA; Jaffe, JH; Johnson, RE; Katz, JL; Rice, KC; Witkin, JM | 1 |
| Bansinath, M; Goldfrank, LR; Shukla, VK; Turndorf, H | 1 |
| Mello, NK | 1 |
| Kamien, JB; Lukas, SE; Mello, NK; Mendelson, JH | 1 |
| Fraser, AD | 1 |
| Charney, DS; Kleber, HD; Kosten, TR; Krystal, JH; Morgan, CH; Price, LH | 2 |
| Bree, MP; Lukas, SE; Mello, NK; Mendelson, JH | 1 |
| Bickel, WK; Bigelow, GE; Jasinski, DR; Johnson, RE; Liebson, IA; Stitzer, ML | 1 |
| Leander, JD | 2 |
| Dykstra, LA; Negus, SS | 1 |
| Hayes, AG; Skingle, M; Tyers, MB | 1 |
| Hynes, MD; Leander, JD; Reel, JK; Zimmerman, DM | 1 |
| Dykstra, LA | 1 |
| France, CP; Woods, JH | 1 |
| Hameroff, SR | 1 |
| France, CP; Jacobson, AE; Woods, JH | 2 |
| Dum, JE; Herz, A | 1 |
| Brown, DR; Holtzman, SG; Locke, KW | 1 |
| Arndt, R; Evans, B; Greenstein, RA; O'Brien, CP; Woody, GE | 1 |
| Kuehnle, JC; Mello, NK; Mendelson, JH; Sellers, ML | 1 |
| Jasinski, DR | 1 |
| Wodak, A | 1 |
| Hoffer, PB; Krystal, JH; McMahon, TJ; O'Connor, PG; Rosen, MI; Sullivan, M; Thomas, HM; van Dyck, CH; Wallace, EA; Woods, SW | 1 |
| Carroll, ME; Comer, SD; Curtis, LK; Lac, ST | 1 |
| House, JD; Makhay, MM; Walker, EA; Young, AM | 1 |
| KOSTEN, TR | 1 |
| Drieze, J; Lukas, SE; Mello, NK; Mendelson, JH | 1 |
| Gold, MS | 1 |
| Greenwood, J; Seivewright, NA | 1 |
| Bigelow, GE; Eissenberg, T; Greenwald, MK; Johnson, RE; Liebson, IA; Stitzer, ML | 1 |
| Bishop, WP; Coffman, BL; Green, MD; King, CD; Owens, IS; Rios, GR; Tephly, TR | 1 |
| Bigelow, GE; Garner, JE; Preston, KL; Sullivan, JT; Walsh, SL | 1 |
| Kamei, J; Nagase, H; Sodeyama, M; Suzuki, T; Tsuda, M | 1 |
| Holtzman, SG | 1 |
| Brandt, MR; Cabansag, SR; France, CP | 1 |
| Carroll, KM; Kosten, TR; O'Connor, PG; Rounsaville, BJ; Schottenfeld, RS; Shi, JM | 1 |
| Blake, AD; Bot, G; Li, S; Reisine, T | 1 |
| Cruz-Madorran, I; Flecknell, PA; Liles, JH; Roughan, J | 1 |
| Morgan, D; Picker, MJ | 1 |
| Allen, JP; Litten, RZ | 1 |
| Bartok, RE; Craft, RM; Heideman, LM | 1 |
| Schuh, KJ; Stitzer, ML; Walsh, SL | 1 |
| Chiang, CT; Demuth, KL; Hoover, DR; Montoya, ID; Preston, KL; Umbricht, A | 1 |
| Bickel, WK; Petry, NM | 1 |
| Eichmiller, PR; Gorelick, DA; Heishman, SJ; Hill, BH; Liberto, JG; Norbeck, J; Rothman, RB | 1 |
| Fiellin, DA; O'Connor, PG | 1 |
| Broom, DC; Coop, A; Guo, L; Husbands, SM; Lewis, JW; Traynor, JR; Woods, JH | 1 |
| Bisaga, A; Popik, P; Radomska, M | 1 |
| Yui, K | 1 |
| David, S; Lancaster, T; Stead, LF | 1 |
| Stimmel, B | 1 |
| Friedland, G; Jatlow, P; Kosten, TR; McCance-Katz, EF; Rainey, PM | 1 |
| Brandt, MR; France, CP; Galici, R | 1 |
| Butelman, E; Kreek, MJ; LaForge, KS | 1 |
| Hall, FS; Mizoguchi, H; Nagase, H; Narita, M; Sora, I; Tseng, LF; Uhl, GR; Wu, HE | 1 |
| Sterious, SN; Walker, EA | 1 |
| Bertschy, G; Besson, J; Bochud Tornay, C; Daeppen, JB; Favrat, B; Monnat, M; Schnyder, C | 1 |
| Compton, M; Ling, W; Rawson, RA | 1 |
| Leitermann, R; Mizoguchi, H; Nagase, H; Spaulding, A; Tseng, LF; Wu, HE | 1 |
| France, CP; McMahon, LR; Sell, SL | 1 |
| Kleber, HD | 1 |
| Colker, AC | 1 |
| Ahmadi, J; Ahmadi, K; Ohaeri, J | 1 |
| Gibbs, AD; Hussain, T; Hussein, Z; McAleer, SD; Mills, RJ; Mullins, FG; Polack, T; Rolan, PE | 1 |
| Tzschentke, TM | 1 |
| Koutsogiannis, Z; Kronborg, I; Lubman, D | 1 |
| Carrigan, KA; Elliott, JC; Lysle, DT; Nelson, CJ; Picker, MJ | 1 |
| Carrigan, KA; Ijames, SG; Lysle, DT; Saurer, TB | 1 |
| Digiusto, E; Mattick, RP; O'Brien, S; Ritter, A; Shakeshaft, A | 1 |
| Bailey, KP | 1 |
| Ali, R; Bell, J; Breen, C; Digiusto, E; Kimber, J; Lintzeris, N; Mattick, RP; Saunders, JB | 1 |
| Holtzman, SG; White, DA | 1 |
| Ali, R; Bell, J; Digiusto, E; Doran, CM; Gilmour, S; Lintzeris, N; Mattick, RP; Saunders, JB; Shanahan, MD; White, J | 1 |
| Collins, ED; Heitler, NE; Kleber, HD; Whittington, RA | 1 |
| O'Connor, PG | 1 |
| O'Brien, CP | 3 |
| Fantoma, A; Gerra, G; Zaimovic, A | 1 |
| Arfken, CL; Koch, AL; Schuster, CR | 1 |
| Miller, MM | 1 |
| Besson, J; Favrat, B | 1 |
| Contreras, JA | 1 |
| de Jong, CJ | 1 |
| Ciccocioppo, R; Economidou, D; Heilig, M; Massi, M; Rimondini, R; Sommer, W | 1 |
| Cubells, JF; Tang, YL; Zhao, C; Zhao, D | 1 |
| Chawarski, MC; Mazlan, M; Schottenfeld, RS | 3 |
| Ng, BY; Peh, LH | 1 |
| David, S; Evins, AE; Lancaster, T; Stead, LF | 1 |
| Becker, GL; France, CP; Gong, ZH; Li, JX; Traynor, JR | 1 |
| Stancliff, S | 1 |
| Brady, KT | 1 |
| Garnick, DW; Hodgkin, D; Horgan, CM; Merrick, EL; Reif, S | 1 |
| Degenhardt, LJ; Gibson, AE | 1 |
| Barr, CS; Heilig, M; Kakko, J; Lidström, J; Svanborg, KD; von Wachenfeldt, J | 1 |
| Gardner, TJ; Kosten, TR | 1 |
| McCann, DJ | 1 |
| Stitzer, ML; Vandrey, R | 1 |
| Tyndale, R | 1 |
| Casadonte, PP; Horton, T; Kolodner, GF; McMurphy, SM | 1 |
| Haile, CN; Kosten, TA; Kosten, TR | 1 |
| Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R | 1 |
| Lee, SS; Merican, MI; Noordin, NM; Rahman, HA; Ramly, R | 1 |
| Newman, RG | 1 |
| Badger, GJ; Dunn, KE; Heil, SH; Higgins, ST; Sigmon, SC | 1 |
| Dolan, K; Larney, S | 1 |
| Amato, L; Davoli, M; Minozzi, S | 1 |
| Reece, AS | 2 |
| Arttamangkul, S; Birdsong, WT; Virk, MS; Williams, JT | 1 |
| Andrian, V; Georgiou, V; Katsakiori, P; Lyros, E; Messinis, L; Panagis, G; Papathanasopoulos, P | 1 |
| Baud, FJ; Chevillard, L; Mégarbane, B; Risède, P | 1 |
| Bramness, J; Gossop, M; Lobmaier, P; Waal, H | 1 |
| Howland, RH | 1 |
| Curran, E; Fishman, MJ; Garrett, S; Subramaniam, G; Winstanley, EL | 1 |
| Chapleo, CB; Hay, JL; La Vincente, SF; Somogyi, AA; White, JM | 1 |
| Metzger, DS; Zhang, Y | 1 |
| Krupitsky, E; O'Brien, CP; Woody, GE; Zvartau, E | 1 |
| Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S | 1 |
| Metzger, DS; O'Brien, CP; Woody, GE | 1 |
| Bergman, J; Paronis, CA | 1 |
| Ambekar, A; Lal, R; Ramdurg, S | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Amato, L; Davoli, M; Kirchmayer, U; Minozzi, S; Vecchi, S; Verster, A | 1 |
| Dodrill, CL; Helmer, DA; Kosten, TR | 1 |
| Law, F; Melichar, J; O'Shea, J | 1 |
| Bart, G | 2 |
| Chawarski, M; Luekens, C; Mazlan, M; Ng, N; Ruger, JP; Schottenfeld, R | 1 |
| Adler, MW; Benamar, K; Brailoiu, E; Brailoiu, GC; Deliu, E; Dun, NJ; Hooper, R; Undieh, AS | 1 |
| Flynn, PM; Friedmann, PD; Frisman, LK; Gordon, M; Hall, E; Hoskinson, R; Kinlock, T; Knight, K; Knudsen, HK; O'Connell, DJ; Sacks, S; Schwartz, R; Shafer, MS; Stein, LA; Welsh, WN | 1 |
| Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT | 1 |
| Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G | 1 |
| Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M | 2 |
| Koob, GF; Misra, KK; Schlosburg, JE; Vendruscolo, LF; Wee, S | 1 |
| Law, F; Melichar, J; O'Shea, J; Praveen, KT | 1 |
| Schaeffer, T | 1 |
| Banks, ML; Negus, SS | 1 |
| Hasson, A; Hillhouse, M; Lindblad, R; Ling, W; McCormack, J; Mooney, LJ; Nielsen, S; Saxon, A; Stablein, D; Thomas, C | 1 |
| Chawarski, M; Mazlan, M; Ng, N; Ruger, JP; Schottenfeld, R | 1 |
| Bailey, CP; Cordery, SF; Delgado-Charro, MB; Guy, RH; Husbands, SM; Ridzwan, IE; Taverner, A | 1 |
| Stitzer, ML | 1 |
| White, J | 1 |
| Clark, N; Verster, A | 1 |
| Bennett, L; Donaldson, LF; Green, A; Kaul, A; Melichar, JK; Mullings, EL; Munafò, MR; Nutt, DJ; O'Shea, J; Sharma, E | 1 |
| Hulse, GK; Reece, AS | 1 |
| Israel, JS; Poore, SO | 1 |
| Douaihy, AB; Kelly, TM; Sullivan, C | 1 |
| David, SP; Evins, AE; Lancaster, T; Prochaska, JJ; Stead, LF | 1 |
| Cummings, GR; Heinrich, CJ | 1 |
| Eastwood, EC; Phillips, TJ | 1 |
| Badger, GJ; Brooklyn, JR; Dunn, KE; Heil, SH; Higgins, ST; Patrick, ME; Saulsgiver, K; Sigmon, SC | 1 |
| Duffy, S; Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; McCool, R; Neilson, M; Perry, AE | 1 |
| Awad, MM; Chakravorty, A; Cheung, JK; Choo, JM; Hiscox, TJ; Lyras, D; Rood, JI | 1 |
| Mannelli, P; Peindl, KS; Swartz, MS; Woody, GE; Wu, LT | 1 |
| Ellayah, D; Hulse, G; Jhugroo, A; Norman, A | 1 |
| Amato, L; Bellisario, C; Davoli, M; Minozzi, S | 1 |
| Falcon, E; Hill-Smith, TE; Lucki, I; Maier, K; Robinson, SA | 1 |
| Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A | 1 |
| Friedmann, PD; Park, TW | 1 |
| Fürst, Z; Hosztafi, S | 1 |
| Meyer, AC; Miller, ME; Sigmon, SC | 1 |
| Du, Y; Ehrich, E; Fava, M; Fernandez, E; Jones, R; Leigh-Pemberton, R; Turncliff, R | 1 |
| Chatterjee, D; Jackson, H; Johnson, K; Mandell, K; Vanness, DJ | 1 |
| Dakwar, E; Kleber, HD | 1 |
| Bisaga, A; Drill, ES; Khan, NA; Mogali, S; Nunes, E; Pavlicova, M; Sullivan, MA | 1 |
| Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; Neilson, M; Perry, AE; Woodhouse, R | 1 |
| Almatroudi, A; Bailey, CP; Bailey, SJ; Husbands, SM | 1 |
| Willyard, C | 1 |
| Maremmani, AG; Maremmani, I; Parrino, MW; Samuels, PN | 1 |
| Aguilar, MA; Miñarro, J; Rodríguez-Arias, M | 1 |
| Cucciare, MA; Garrison-Diehn, C; Schultz, NR; Timko, C; Vittorio, L | 1 |
| Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME | 1 |
| Bai, SA; Darpo, B; Ferber, G; Finn, A; Xiang, Q; Zhou, M | 1 |
| Binswanger, I; Blue-Howells, J; Clark, S; Finlay, AK; Frayne, SM; Harris, AH; McGuire, J; Oliva, E; Rosenthal, J; Smelson, D; Timko, C | 1 |
| Bodkin, JA; de Somer, M; DiPetrillo, L; Du, Y; Ehrich, E; Fava, M; Leigh-Pemberton, R; Memisoglu, A; Silverman, B; Thase, ME; Trivedi, MH | 1 |
| Ling, W | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Matteucci, AM; Reif, S; Stewart, MT | 1 |
| Anderson, B; Bailey, G; Herman, D; Stein, M; Uebelacker, LA | 1 |
| Klein, JW | 1 |
| Barnett, G; Bruner, A; Fishman, M; Sharma, B | 1 |
| Ayanga, D; Kosten, TR; Shorter, D | 1 |
| Browne, CA; Erickson, RL; Lucki, I; Robinson, SA | 1 |
| Blazina, I; Bougatsos, C; Chou, R; Devine, B; Grusing, S; Korthuis, PT; McCarty, D; Weimer, M; Zakher, B | 1 |
| Colucci, S; Harris, SC; Morganroth, J; Ripa, SR; Thorn, MD | 1 |
| Alagoz, E; Gustafson, DH; Johnson, RA; Kornfield, R; Landucci, G; Mares, ML; McTavish, F; Pe-Romashko, K; Quanbeck, A; Shah, D; Thomas, C; Westergaard, RP | 1 |
| Bisaga, A; Carpenter, KM; Choi, CJ; Dakwar, E; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Sullivan, M | 1 |
| Brooks, EP; Martin-Flores, M; Mitchell, LM; Singh, B; Taylor, L; Walsh, CA | 1 |
| Woody, GE | 1 |
| Gryczynski, J; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A | 1 |
| Hulse, G; Kelty, E | 4 |
| Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM | 1 |
| Feder, KA; Krawczyk, N; Saloner, B | 1 |
| Hadland, SE; Larochelle, MR; Samet, JH; Schuster, MA; Wharam, JF; Zhang, F | 1 |
| Ciccocioppo, R; de Guglielmo, G; Journigan, VB; Kallupi, M; Shen, Q; Yasuda, D; Zaveri, NT | 1 |
| Bigelow, GE; Dunn, KE; Strain, EC; Tompkins, DA | 1 |
| Leff, JA; Linas, BP; Morgan, JR; Schackman, BR; Walley, AY | 1 |
| Bernstein, SL; D'Onofrio, G | 1 |
| Alto, W; Gianutsos, P; Mancl, L; Plawman, A; Rudolf, G; Rudolf, V; Walsh, J | 1 |
| Carton, L; Gaboriau, L; Lescut, C; Rolland, B | 1 |
| Brown, R; Collier, E; Haram, E; Horst, J; Jacobson, N; Kim, JS; Knudsen, HK; Madden, L; Molfenter, T; Starr, S; Toy, A; Van Etten, M | 1 |
| Chang, DC; Fairbairn, N; Klimas, J; Wood, E | 1 |
| Abraham, AJ; Andrews, CM; D'Aunno, T; Friedmann, PD; Grogan, CM; Humphreys, K; Pollack, HA | 1 |
| Desai, N; Kelly, MM; Quiñones, T; Reilly, E; Rosenheck, R | 1 |
| Becker, K; Diamant, AL; Ewing, B; Heinzerling, K; Hunter, SB; Lamp, K; Lind, M; Ober, AJ; Osilla, KC; Setodji, CM; Watkins, KE | 1 |
| Bagley, SM; Carney, BL; Hadland, SE | 1 |
| Atreja, N; Duncan, M; Gore, M; Shah, A; Tai, KS | 1 |
| Andraka-Christou, B; Capone, MJ | 1 |
| Alexander-Scott, N; Boss, R; Brinkley-Rubinstein, L; Clarke, J; Green, TC; Marshall, BDL; Rich, JD | 1 |
| Honermann, B; Jones, A; Kutsa, O; Millett, G; Sharp, A; Sherwood, J | 1 |
| Ho, RC; McIntyre, RS; Ragguett, RM; Rong, C; Rosenblat, JD | 1 |
| Akerman, SC; Bisaga, A; Graham, CE; Kosten, TR; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Tompkins, DA; Yu, M | 1 |
| Azhar, G; Chen, C; Hempel, S; Maglione, MA; Maksabedian, E; Newberry, S; Raaen, L; Shahidinia, N; Shanman, RM; Shen, M | 1 |
| Graham, DP; Kosten, TR; Nielsen, DA | 1 |
| Balhara, YPS; Gupta, R; Sarkar, S; Shah, B | 1 |
| Quaye, AN; Ward, EN; Wilens, TE | 1 |
| Bisaga, A; Campbell, AN; Crystal, S; Friedmann, PD; Johnson, KA; Levin, FR; Nunes, EV; Olfson, M; Pincus, HA; Remien, RH; Williams, AR | 1 |
| Bagley, SM; Bernson, D; Land, T; Larochelle, MR; Liebschutz, JM; Stopka, TJ; Walley, AY; Wang, N; Xuan, Z | 1 |
| Bao, YP; Blow, FC; Degenhardt, L; Farrell, M; Ilgen, M; Li, JQ; Liu, MX; Lu, L; Ma, J; Shi, J; Su, MF; Wang, RJ | 1 |
| Alexander, GC; Saloner, B; Stoller, KB | 1 |
| Mannelli, P; Swartz, M; Wu, LT | 1 |
| Aschenbrenner, DS | 1 |
| Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J | 1 |
| Aggarwal, AK; Harrison, TK; Kornfeld, H; Lembke, A | 1 |
| Haffajee, RL; Weintraub, E; Yang, YT | 1 |
| Barbosa-Leiker, C; Campbell, ANC; Greenfield, SF; Hatch-Maillette, M; Mennenga, SE; Mitchell, SG; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Saraiya, T; Scodes, J | 1 |
| Arnelle, D; Bidlack, JM; Deaver, DR; Fern Toh, M; Knapp, BI; Namchuk, MN; Pin, SS; Plotnikava, M; Wonsey, AM | 1 |
| Clarke, JG; Gresko, SA; Martin, RA; Rich, JD | 1 |
| Bagley, SM; Hadland, SE; Larochelle, MR; Levy, S; Rodean, J; Samet, JH; Silverstein, M; Zima, BT | 1 |
| Broglio, K; Matzo, M | 1 |
| Banks, ML; Negus, SS; Schwienteck, KL | 1 |
| Binswanger, IA; Bowe, T; Finlay, AK; Harris, AHS; Smelson, D; Stimmel, MA; Timko, C; Yu, M | 1 |
| Ehrich, E; Fava, M; Martin, WF; Memisoglu, A; Nangia, N; Pathak, S; Stanford, AD; Thase, ME; Trivedi, MH; Yu, M | 1 |
| Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Sanchez, C; Smith, KL | 1 |
| Grahan, B | 1 |
| Gordon, MS; Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, MM; Mitchell, SG; O'Grady, KE; Schwartz, RP | 1 |
| Burke, NN; Deaver, DR; Ferdousi, M; Finn, DP; Kelly, JP; Roche, M | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, A; Schmidt, EM; Timko, C; Wong, JJ | 1 |
| Kaplan, L | 1 |
| Ali, R; Hu, L; Marsden, J; Rush, AJ; Tai, B; Volkow, N | 1 |
| Barry, CL; Mauro, C; Mojtabai, R; Olfson, M; Wall, MM | 1 |
| Abraham, AJ; Adams, GB; Bradford, AC; Bradford, WD | 1 |
| Fanucchi, L; Korthuis, PT; Springer, SA | 1 |
| McKee, SA; Moore, KE; Oberleitner, LMS; Reid, HH; Roberts, W; Smith, KMZ | 1 |
| Heller, NM; Maher, DP; Walia, D | 1 |
| Butler, F; Witt, L | 1 |
| Hulse, G; Joyce, D; Kelty, E | 1 |
| Barnett, BS; Suzuki, J; Ward, HB | 1 |
| Barnes, DE; Marton, T; Wallace, A; Woolley, JD | 1 |
| Barry, CL; Gollust, SE; Kennedy-Hendricks, A; Levin, J; McGinty, EE; Stone, E | 1 |
| Rosenberg, L | 1 |
| Barry, CL; Landis, R; Saloner, B; Stein, BD | 1 |
| Cami-Kobeci, G; Czoty, PW; Davenport, AT; Epperly, PM; Flynn, SM; Husbands, SM; Ko, MC | 1 |
| Landau, R | 1 |
| Dzau, VJ; Leshner, AI | 1 |
| Bailey, CP; Cordery, SF; Delgado-Charro, MB; Guy, RH; Husbands, SM | 1 |
| Linas, BP; Morgan, JR; Schackman, BR; Walley, AY; Weinstein, ZM | 1 |
| Duello, A; Green, L; Horn, P; Presnall, N; Rudder, T; Stringfellow, E; Winograd, RP; Wood, C | 1 |
| Allan, GM; Dugré, N; Finley, CR; Garrison, S; Kolber, MR; Korownyk, C; Lindblad, AJ; Perry, D; Thomas, B; Ting, R; Ton, J; Vandermeer, B; Yang, PR | 1 |
| Banken, R; Kumar, VM; Otuonye, IS; Pearson, SD | 1 |
| Choi, S; Healy, S; Neighbors, CJ; Shapoval, L; Sun, T; Yerneni, R | 1 |
| Bodkin, JA; Claxton, A; Fava, M; Martin, W; Memisoglu, A; Pathak, S; Stanford, AD; Thase, ME; Trivedi, MH; Yu, M | 1 |
| Carter, G; Jones, H; Miller, M; Saia, K; Shrestha, H; Valle, E; Wachman, EM; Werler, M | 1 |
| Glance, JB; Gopalan, P; Kmiec, J; Spada, M | 1 |
| Bridgeman, PJ; Koehl, JL; Zimmerman, DE | 1 |
| Katz, E; Towers, CV; Visconti, K; Weitz, B | 1 |
| Lin, MP; Manini, AF; Richardson, LD; Shastry, S | 1 |
| Bell, J; Strang, J | 1 |
| Chemi, C; Dickson, V; Lee, JD; Suhail-Sindhu, S; Tofighi, B; Williams, AR | 1 |
| Camenga, DR; Colon-Rivera, HA; Muvvala, SB | 1 |
| Burke, NN; Deaver, DR; Eyerman, DJ; Finn, DP; Kelly, JP; Li, Y; Roche, M; Sanchez, C | 1 |
| Alam, F; Dhadley, S; Roberts, P; Townley, J; Webster, R; Wright, N | 1 |
| Gold, MS; Oesterle, TS; Rummans, TA; Thusius, NJ | 1 |
| Badolato, R; Flannery, M; Garment, AR; Giftos, J; Lee, JD; McDonald, RD; Tofighi, B; Velasquez, M; Vittitow, A | 1 |
| Coffa, D; Snyder, H | 1 |
| Bagley, SM; Bernson, D; Hadland, SE; Land, T; Larochelle, MR; Patel, A; Samet, JH; Silverstein, M; Walley, AY; Wang, N; Xuan, Z | 1 |
| Humphreys, K; Shover, CL | 1 |
| Byrd, DJ; Campbell, TB; Clarke, TJ; Jones, CM; McCance-Katz, EF; Ohuoha, C | 1 |
| Brown, JN; Elias, AM; Pepin, MJ | 1 |
| Blanco, C; Volkow, ND | 1 |
| Brezel, ER; Fox, AD; Powell, T | 1 |
| Felix, C; Olsen, Y; Sharfstein, JM | 1 |
| Bisaga, A; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Sibai, M | 1 |
| Bardo, MT; Beckmann, JS; Hammerslag, LR; Hofford, RS; Kang, Q; Kryscio, RJ | 1 |
| Banta-Green, CJ; Floyd, AS; Hoeft, TJ; Sears, JM; Tsui, JI; Williams, JR | 1 |
| Johnson, JA; Liebschutz, JW; Martin, B; Montgomery, MW; Mosquera, M; Price, CD; Robinson, D; Schnipper, JL; Solomon, DA; Suzuki, J; Weiss, RD | 1 |
| Hulme, J; Sheikh, H; Wiercigroch, D | 1 |
| Banks, ML; Negus, SS; Townsend, EA | 1 |
| Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A | 1 |
| Budney, AJ; Marsch, LA; Metcalf, SA; Moore, SK; Saunders, EC; Scherer, E; Walsh, O | 1 |
| Braucht, G; Howell, J; Mericle, A; Miles, J; Sheridan, D | 1 |
| Agus, D; Fingerhood, M; Krawczyk, N; Lyons, BC; Mojtabai, R; Saloner, B; Stuart, EA; Weiner, JP | 1 |
| Babakhanlou-Chase, H; Bernson, D; Land, T; Larochelle, MR; Li, Y; Lodi, S; Walley, AY | 1 |
| Fuehrlein, B; Jaeger, S | 1 |
| Eitan, S; Madison, CA | 1 |
| Hulse, G; Joyce, D; Kelty, E; Preen, DB | 1 |
| Ahmedani, B; Arnsten, JH; Binswanger, IA; Bobb, JF; Boudreau, DM; Braciszewski, JM; Bradley, KA; Campbell, CI; Cunningham, CO; Glass, JE; Hechter, RC; Horigian, VE; Johnson, EA; Lapham, G; Liu, D; Matthews, AG; McCormack, J; Murphy, MT; Rossom, RC; Samet, JH; Saxon, AJ; Schwartz, RP; Szapocznik, J; Yarborough, BJ; Zare, M | 1 |
| Altice, FL; Bromberg, DJ; Nyhan, K; Refsland, BM; Stanojlović, M; Viera, A; Whittaker, S | 1 |
| Akerman, SC; Alam, D; Comer, SD; Douaihy, A; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Zavod, A | 1 |
| Wakeman, SE | 1 |
| Robinson, CA; Wilson, JD | 1 |
| Andraka-Christou, B; Atkins, D; Madeira, J; Silverman, RD | 1 |
| Chen, R; Disney, A; Dripps, IJ; Husbands, SM; Jutkiewicz, EM; Livingston, KE; Rice, KC; Shafer, AM; Traynor, JR | 1 |
| Fine, M; Herscher, M; Hirt, L; Navalurkar, R; Wang, L | 1 |
| Burden, J; Codell, NK; Drexler, K; Dungan, MT; Gordon, AJ; Hagedorn, H; Hawkins, EJ; Mhatre-Owens, A | 1 |
| Chalhoub, RM; Kalivas, PW | 1 |
| Aharonovich, E; Akerman, SC; Kosten, T; Lopez-Bresnahan, M; Nangia, N; Sullivan, MA; Zavod, A | 1 |
| Bachhuber, MA; Barry, CL; Kennedy-Hendricks, A; McGinty, EE; Stone, E | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Ameli, O; Azocar, F; Chaisson, CE; Crown, WH; Larochelle, MR; McPheeters, JT; Sanghavi, DM; Wakeman, SE | 1 |
| Andraka-Christou, B; Attermann, J; Beck, AJ; Buche, J; Cupito, A; Haffajee, RL | 1 |
| Andraka-Christou, B; Atkins, D | 1 |
| Calleo, VJ; Sullivan, RW; Szczesniak, LM | 1 |
| Biondi, BE; Cioe, K; Easly, R; Simard, A; Springer, SA; Zheng, X | 1 |
| Anderson, J; Bourne, D; Mackey, K; Peterson, K; Veazie, S | 1 |
| Bourne, D; Mackey, K; Peterson, K; Veazie, S | 1 |
| Allen, J; Beauchamp, GA; Boateng, N; Burmeister, DB; Esposito, SB; Laubach, LT; Lauber, P; Roth, P; Shaak, S; Yazdanyar, A | 1 |
| Baron, CA; Blinova, K; Johannesen, L; Patel, D; Randolph, AL; Ren, M; Sheng, J; Strauss, DG; Thiebaud, N; Tran, PN; Volpe, DA; Wu, M; Wu, WW | 1 |
| Bohnert, ASB; Foxman, B; Gicquelais, RE; Thomas, L | 1 |
| Donelan, CJ; Evans, EA; Hayes, E; Potee, RA; Schwartz, L | 1 |
| Fishman, M; Wenzel, K | 1 |
| Blue, TR; Couvillion, K; Danner, ML; Fishman, MJ; Gordon, MS; Jarvis, DK; Maher, K; Mitchell, SG; Murphy, SM; Ryan, D; Vocci, FJ; Wenzel, K | 1 |
| Crawford, TN; Fischer, KB; Gainer, DM; Wright, MD | 1 |
| Basaraba, C; Bisaga, A; Brooks, DJ; Choi, CJ; Levin, FR; Mahony, AL; Mariani, JJ; Naqvi, N; Pavlicova, M | 1 |
| Board, A; Guy, GP; Jones, CM | 1 |
| Acion, L; Arndt, S; Hedden, S; Lynch, AC; Sabbagh, S; Weber, AN | 1 |
| Baratta, JL; Ferd, P; Patel, N; Schwenk, ES; Torjman, MC; Viscusi, ER | 1 |
| Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Bergeria, CL; Dunn, KE; Huhn, AS; Nayak, SM; Strain, EC | 1 |
| Costello, E; Novo, P; Nunes, EV; Rotrosen, J; Shulman, M; Weiss, R | 1 |
| Adekoya, P; Gulati, A; Hunter, C; Jones, MR; Kaye, AD; Kaye, AM; Kuppalli, S; Orhurhu, V; Seth, R; Urits, I | 1 |
| Bachireddy, C; Terplan, M | 1 |
| Freeman, PR; Huang, Z; Oser, C; Sohn, M; Talbert, JC | 1 |
| Campbell, ANC; Choo, TH; Haenlein, P; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M; Tofighi, B; Wai, J | 1 |
| Beckwith, N; Bell, K; Cheng, A; Farabee, D; Goldfeld, K; Groblewski, T; Gryczynski, J; Harding, K; Lee, JD; Malone, M; Marsch, LA; Martin, W; McDonald, RD; Monico, L; Nyaku, A; Reeves, R; Saunders, EC; Schwartz, RP; Springer, SA; Suchocki, A; Talon, K; Torralva, R; Violette, S; Waddell, EN; Wisdom, JP | 1 |
| García, MC | 1 |
| Ahmed, S; Galbis-Reig, D; Hybki, B; Penders, T; Stanciu, C | 1 |
| Bain, PA; Carrero, ND; Chatterjee, A; Li, R; McLaughlin, MF | 1 |
| Gehlert, DR; Li, K; Medina, JC; Schwartz, N; Youngblood, B | 1 |
| Fishman, M; Lavorato, L; Selby, V; Thomas, J; Wenzel, K; Wildberger, J | 1 |
| Assoumou, SA; Barocas, J; Chatterjee, A; Hadland, SE; Linas, BP; Morgan, JR; Murphy, SM; Walley, AY | 1 |
| Adam, GP; Balk, EM; Becker, SJ; Danko, KJ; Helseth, SA; Saldanha, IJ; Scott, K; Steele, DW | 1 |
| Campbell, ANC; Montgomery, L; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Twitty, D; Wang, AL; Winhusen, T | 1 |
| Cao, DN; Li, F; Li, J; Wu, N | 1 |
| Chaisson, CE; Ciemins, E; Larochelle, MR; Morgan, JR; Quinn, EK; Stempniewicz, N; White, LF | 1 |
| Fong, C; Matusow, H; Rosenblum, A | 1 |
| Hallahan, JE; Hillhouse, TM; Husbands, SM; Jutkiewicz, EM; Koppenhaver, PO; Meurice, C; Olson, KM; Ostovar, M; Rysztak, LG; Sears, BF; Traynor, JR; West, JL | 1 |
| Bandara, S; Barry, CL; Kennedy-Hendricks, A; Merritt, S; Saloner, B | 1 |
| Nalven, T; Schick, MR; Spillane, NS; Weyandt, LL | 1 |
| Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY | 1 |
| Ahrens, K; Allen, L; Austin, A; Barnes, AJ; Burns, M; Chang, CH; Clark, S; Cole, E; Crane, D; Cunningham, P; Donohue, JM; Gordon, AJ; Idala, D; Jarlenski, MP; Junker, S; Kennedy, S; Kim, JY; Lanier, P; Mauk, R; McDuffie, MJ; Mohamoud, S; Pauly, N; Sheets, L; Talbert, J; Tang, L; Zivin, K | 1 |
| Beas, I; Bromley, E; Hunter, SB; Hurley, B; Leamon, I; Martinez, J; McCreary, M; McCullough, CM; Montero, A; Ober, AJ; Sheehe, J; Tarn, DM; Watkins, KE | 1 |
| Komrowski, MD; Sekhri, NK | 1 |
| Cinemre, B; Coşkun, MN; Erdoğan, A; Kulaksızoğlu, B; Kuloğlu, MM; Topcuoğlu, M | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE | 1 |
| Gainer, DM; Miller, SC; Nahhas, RW; Silverstein, SM; Vanderhoof, SO; Vanderhoof, T; Wright, MD | 1 |
| Light, T; Madden, EF; Prevedel, S; Sulzer, SH | 1 |
| Hochheimer, M; Unick, GJ | 1 |
| Cook, RR; Fanucchi, L; Foot, C; King, C; Korthuis, PT; Lucas, GM; Lum, PJ; Rodriguez, A; Tookes, H; Torralva, R; Vergara-Rodriguez, P; Waddell, EN | 1 |
| Brown, R; Haram, E; Horst, J; Jacobson, N; Kim, H; Kim, JS; Knudsen, HK; Madden, LM; Molfenter, T | 1 |
| Buie, R; Chastain, C; Dear, ML; Edwards, DA; Kast, KA; Limper, HM; Lindsell, CJ; Marcovitz, DE; Sullivan, W; White, KD | 1 |
| McClellan, C; Moriya, A; Simon, K | 1 |
| Allen, LR; Manini, AF; Nobel, I; Richardson, LD; Shastry, S; Vidal, K | 1 |
| Akerman, SC; Douaihy, AB; Legedza, A; Mannelli, P; Sullivan, MA; Zavod, A | 1 |
| Cotton, AJ; Kurtz, FB; Lo, K; Waldbauer, L | 1 |
| Anderson, BJ; Bailey, GL; Conti, M; Herman, DS; Stein, MD; VanNoppen, D | 1 |
| Barrow, J; Choudhary, A; Simon, L; Ticku, S; Tobey, M | 1 |
| Laks, J; Peterkin, A; Weinstein, ZM | 1 |
| Birkeland, B; Brenna, IH; Løberg, EM; Marciuch, A; Røstad, B; Solli, KK; Tanum, L; Veseth, M; Weimand, B | 1 |
| Bromberg, DJ; Karamouzian, M; Pilarinos, A | 1 |
| Ashmead, R; Bailey, E; Bickert, T; Bonny, AE; Doogan, NJ; Mack, A; Schmidt, S; Tossone, K; Zhang, P | 1 |
| Chaisson, CE; Ciemins, E; LaRochelle, MR; Linas, BP; Morgan, JR; Quinn, EK; Stempniewicz, N; Walley, AY; White, LF | 1 |
| Asher, A; Board, A; Cremer, LJ; Guy, GP; Parker, EM; Schieber, L | 1 |
| Amaducci, AM; Beauchamp, GA; Hanisak, JL; Koons, AL; Laskosky, J; Maron, BM; McLoughlin, TM | 1 |
| Fradkin, D; Kameg, B; Lepore, M | 1 |
| Akerman, SC; Douaihy, AB; Fratantonio, J; Legedza, A; Mannelli, P; Sullivan, MA; Zavod, A | 1 |
| Beck, M; Kay, A; Shmuts, R | 1 |
| Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X | 1 |
| Domino, ME; Grove, LR; Rao, N | 1 |
| Graham, DP; Hamon, SC; Hillhouse, M; Kosten, TR; Lawson, WB; Ling, W; Nielsen, DA; Nielsen, EM; Rotrosen, J; Saxon, AJ; Settles-Reaves, BD; Shmueli-Blumberg, D; Shores-Wilson, K; Trivedi, MH; Walker, R | 1 |
| Anderson-Harper, R; Duello, A; Gochez-Kerr, T; Lohmann, B; Miles, J; Richardson, K; Winograd, RP; Wood, CA | 1 |
| Biondi, BE; Schlossberg, EF; Shaw, A; Springer, SA; Vander Wyk, B | 1 |
| Dromgoole, D; Ghanem, N; Hussein, A; Jermyn, RT | 1 |
| Douros, A; Farhat, I; Lim, J; Panagiotoglou, D | 1 |
| Carter, I; DeWitt, C; Forsgren, E; McCollough, M; Philippine, T; Taira, BR | 1 |
| Anguiano, V; Joudrey, PJ; Kolak, M; Lin, Q; Paykin, S; Wang, EA | 1 |
| Bierut, LJ; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 2 |
| Campbell, ANC; Choo, TH; Cook, RR; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Tsui, JI | 1 |
| Billeci, D; Candeletti, S; Coluzzi, F; Losapio, LM; Rocco, M; Romualdi, P; Rullo, L; Scerpa, MS | 1 |
| Anselin, L; Kolak, M; Lin, Q; Pollack, H; Schneider, J; Taylor, B; Watts, B | 1 |
| Crystal, S; Gupta, S; Miles, J; Nguyen, T; Samples, H; Simon, K; Ziedan, E | 1 |
| Biondi, BE; Di Paola, A; Forray, A; Frank, CA; Shaw, A; Springer, SA; Taweh, N | 1 |
| Donohoe, T; Garner, BR; Gordon, T; Gotham, HJ; Knudsen, HK; Loyd, K; Martin, EG; Toro, AK; Tueller, SJ; Zulkiewicz, BA | 1 |
| Dunphy, CC; Guy, GP; Xu, L; Zhang, K | 1 |
| Angermaier, G; Carswell, N; Castaneda, C; Delgado, F | 1 |
| Abare, M; Chyorny, A; Olson, M; Wilhelm-Leen, E; Will, J | 1 |
| Berro, LF; Freeman, KB; Rowlett, JK; Talley, JT; Zamarripa, CA | 1 |
| Casey, SK; Irvin, JR; Kane, MT; Kehoe, L; McGovern, S; Powell, EA; Regan, S; Rodriguez, W; Wakeman, SE; Yacorps, GM | 1 |
| Berk, J; Clarke, JG; Fritsche, J; Kang, A; Martin, RA; Rich, JD | 1 |
| Andraka-Christou, B; Buche, J; Haffajee, RL; Page, C; Schoebel, V | 1 |
| Campbell, ANC; Choo, TH; Fishman, M; Greiner, MG; Lee, JD; Novo, P; Nunes, EV; Opara, O; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M | 1 |
| Di Paola, A; Lier, AJ; Seval, N; Springer, SA; Vander Wyk, B | 1 |
| Agius, E; Kollin, R; Lee, G; Madden, EF; Pasman, E; Resko, SM; Rodriguez, B | 1 |
| Blanco, C; Compton, WM; Hodges, K; Jones, CM; Ling, SM; Losby, JL; Shoff, C | 1 |
| Brown, R; Haram, E; Horst, J; Jacobson, N; Kim, H; Kim, JS; Kisicki, A; Knudsen, HK; Madden, LM; Molfenter, T; Toy, A | 1 |
| Bolton, J; Hoang, H; Laiteerapong, N; Marsh, J; Murugesan, M; Nocon, R; Peterson, L; Pollack, H | 1 |
| Acuña, AM; Leyrer-Jackson, JM; Olive, MF | 1 |
| Cheng, A; Garrity, K; Hey, SP; Lee, JD; Lindquist, K; Malone, M; McDonald, R; McNeely, J; Pace, N; Roberts, T; Schatz, D; Sugarman, A; Tofighi, B; Vittitow, A; Williams, O | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT | 1 |
| Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K | 1 |
| Konakanchi, JS; Sethi, R | 1 |
| Choo, TH; Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Vest, N; Wenzel, K | 1 |
| Arah, OA; Cook, RR; Foot, C; Humphreys, K; Korthuis, PT; Levander, XA; Luo, SX; Rudolph, KE; Tsui, JI | 1 |
| Balise, RR; Brandt, L; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Odom, GJ | 1 |
| Bisaga, A; Dresser, L; Fishman, M; Ghitza, UE; Greiner, MG; Hamilton, A; Hefner, K; Ho, R; Jelstrom, E; Nunes, EV; Opara, O; Potter, K; Rotrosen, J; Scheele, C; Shulman, M; Tafessu, HM; Voronca, DC | 1 |
| Batty, E; Booty, M; Eddens, K; Knudsen, HK; Oser, CB; Perry, B; Rockett, M; Staton, M | 1 |
| Rodriguez, CP; Suzuki, J | 1 |
| Chatterjee, A; Linas, BP; Macmadu, A; Madushani, RWMA; Murphy, SM; Potee, RA; Ryan, D; Savinkina, A; Walley, AY; Weitz, M | 1 |
| Batty, E; Booty, MD; Harp, K; Knudsen, HK; Oser, CB; Staton, M | 1 |
| Cox, KM; Doyle, M; Marsch, LA; McLeman, BM; Murray, OB; Ryer, J; Saunders, EC; Watts, D | 1 |
| Cornett, EM; Edinoff, AN; Flanagan, CJ; Jackson, ED; Kaye, AD; Kaye, AM; Pearl, NZ; Sinnathamby, ES; Wenger, DM | 1 |
| Barnett, ML; Chyn, D; Hardy, B; Huskamp, HA; Lewinson, T; Meara, E; Mehrotra, A; Morden, NE; Onsando, M | 1 |
| Haigney, MCP; Kao, DP; Kleiman, RB; Klein, M; Krantz, MJ; Rudo, TJ; Stockbridge, N | 1 |
| Campbell, ANC; Fishman, M; Gopaldas, M; Jalali, A; Murphy, SM; Nunes, EV; Rotrosen, J; Wenzel, K | 1 |
| Berger, NA; Davis, PB; Kaelber, DC; Volkow, ND; Wang, L; Xu, R | 1 |
| Balise, RR; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Rotrosen, J; Saxon, AJ; Weiss, RD | 1 |
| Boyett, B; Hassman, D; Learned, SM; Rutrick, D; Shinde, S; Zhao, Y | 1 |
| Cooke, E; Galati, BM; Kelly, JC; Rogers, CE; Wenzinger, M | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kloster, PS; Kunøe, N; Opheim, A; Solli, KK; Tanum, L | 1 |
| Baston, KE; Ganetsky, VS; Haroz, R; Heil, J; Hunter, K; Milburn, C; Salzman, M; Schmidt, R | 1 |
| Addis, M; Altschuler, A; Arnsten, JH; Bart, G; Bobb, JF; Boudreau, DM; Braciszewski, JM; Bradley, KA; Burganowski, RP; Caldeiro, RM; Campbell, CI; Cunningham, CO; Dryden, D; Ghiroli, MM; Glass, JE; Hamilton, LK; Horigian, VE; Hu, Y; Hyun, N; Idu, AE; Labelle, CT; LaHue, JS; Lapham, GT; Lee, AK; Liebschutz, JM; Liu, DS; Loree, AM; Matthews, AG; McCormack, J; McNeely, J; Merrill, JO; Murphy, MT; Murphy, SM; Northrup, TF; Phillips, RC; Qiu, H; Samet, JH; Saxon, AJ; Schwartz, RP; Shea, M; Shmueli-Blumberg, D; Silva, AJ; Stotts, AL; Szapocznik, J; Tsui, JI; Wartko, PD; Weinstein, ZM; Wong, MT; Yu, O; Zare-Mehrjerdi, M | 1 |
110 review(s) available for naltrexone and buprenorphine
| Article | Year |
|---|---|
Preclinical evaluation of the effects of buprenorphine, naltrexone and desipramine on cocaine self-administration.
Topics: Animals; Buprenorphine; Cocaine; Desipramine; Humans; Macaca mulatta; Naltrexone; Self Administration | 1990 |
Clinical toxicology of drugs used in the treatment of opiate dependency.
Topics: Buprenorphine; Clonidine; Humans; Methadone; Methadyl Acetate; Naltrexone; Opioid-Related Disorders | 1990 |
Clinical investigations of drug effects in women.
Topics: Buprenorphine; Cocaine; Desipramine; Female; Heroin Dependence; Humans; Male; Naltrexone; Opioid-Related Disorders; Sex Factors; Substance-Related Disorders | 1986 |
Behavioral pharmacology of buprenorphine.
Topics: Adult; Animals; Buprenorphine; Conditioning, Operant; Eating; Heroin Dependence; Humans; Macaca; Male; Methadone; Morphinans; Naltrexone; Opioid-Related Disorders; Reinforcement, Psychology; Self Administration | 1985 |
Opiate receptor pharmacology: mixed agonist/antagonist narcotics.
Topics: Analgesics, Opioid; Buprenorphine; Butorphanol; Endorphins; Humans; Nalbuphine; Nalorphine; Naloxone; Naltrexone; Narcotic Antagonists; Pentazocine; Receptors, Opioid | 1983 |
Managing illicit drug use. A practical guide.
Topics: Buprenorphine; Counseling; Disulfiram; Humans; Methadone; Methadyl Acetate; Naltrexone; Psychotherapy; Self-Help Groups; Substance Abuse Treatment Centers; Substance-Related Disorders | 1994 |
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1993 |
What is important in drug misuse treatment?
Topics: Buprenorphine; Clonidine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders; United Kingdom | 1996 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
Pharmacologic treatment of heroin-dependent patients.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Heroin Dependence; Humans; Mental Disorders; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Physician's Role; Substance Withdrawal Syndrome | 2000 |
[Contemporary methods in pharmacotherapy in the opiate dependent treatment].
Topics: Adrenergic alpha-Agonists; Buprenorphine; Clonidine; Heroin Dependence; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Narcotic Antagonists; Narcotics | 2000 |
Opioid antagonists for smoking cessation.
Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation | 2001 |
Pharmacotherapy of addictions.
Topics: Alcoholism; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2002 |
Pharmacologic treatments for heroin and cocaine dependence.
Topics: Buprenorphine; Clonidine; Cocaine-Related Disorders; Comorbidity; Heroin Dependence; Humans; Mental Disorders; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics | 2003 |
Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Buprenorphine; Drug Therapy; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; United States | 2002 |
Pharmacological treatments for substance use disorders.
Topics: Adrenergic beta-Antagonists; Alcohol Deterrents; Anti-Anxiety Agents; Benzodiazepines; Buprenorphine; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neurobiology; Neuropharmacology; Psychopharmacology; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics | 2006 |
Opioid antagonists for smoking cessation.
Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation | 2006 |
Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
Topics: Buprenorphine; Comorbidity; Delayed-Action Preparations; Drug Administration Schedule; Drug Design; Drug Therapy, Combination; Humans; Mental Disorders; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2008 |
Contingency management: utility in the treatment of drug abuse disorders.
Topics: Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Humans; Motivation; Naltrexone; Narcotic Antagonists; Patient Compliance; Receptors, Opioid, mu; Reinforcement, Psychology; Reward; Substance Abuse Detection; Substance Abuse Treatment Centers; Substance-Related Disorders; Treatment Outcome | 2008 |
Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Topics: Alcoholism; beta-Endorphin; Buprenorphine; Cytochrome P-450 CYP2D6; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Opioid, mu | 2008 |
A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?
Topics: Buprenorphine; Heroin Dependence; HIV Infections; Humans; International Cooperation; Methadone; Naltrexone; Narcotic Antagonists; Patient Care; Prisoners; Prisons | 2009 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2009 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Support; Substance Withdrawal Syndrome | 2010 |
Drug treatment as HIV prevention: expanding treatment options.
Topics: Alcoholism; Buprenorphine; Clinical Protocols; Drug Users; Health Promotion; HIV Infections; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Risk Reduction Behavior; Risk-Taking; Substance Abuse, Intravenous; Substance-Related Disorders | 2010 |
Heroin anticraving medications: a systematic review.
Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2010 |
Drug treatment as HIV prevention: a research update.
Topics: Anti-HIV Agents; Buprenorphine; Guideline Adherence; HIV Infections; Humans; Naltrexone; Risk Reduction Behavior; Sexual Behavior | 2010 |
Oral naltrexone maintenance treatment for opioid dependence.
Topics: Administration, Oral; Benzodiazepines; Buprenorphine; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2011 |
Prescription pain medication dependence.
Topics: Analgesics; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pain; Prescription Drugs; Substance-Related Disorders | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Heroin Dependence; Humans; Incidence; Methadone; Naltrexone; Opioid-Related Disorders | 2009 |
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Topics: Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Maintenance medication for opiate addiction: the foundation of recovery.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2012 |
Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
Topics: Analgesics, Opioid; Buprenorphine; Chemistry, Pharmaceutical; Dextroamphetamine; Humans; Lisdexamfetamine Dimesylate; Morphine; Naltrexone; Opioid-Related Disorders; Pain; Prescription Drug Misuse; United States; United States Food and Drug Administration | 2012 |
Medications development for opioid abuse.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Endocannabinoids; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neuroglia; Opioid-Related Disorders; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2013 |
Medications for substance use disorders.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder | 2013 |
Opioid antagonists for smoking cessation.
Topics: Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Cessation Devices | 2013 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2013 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Maintenance Chemotherapy; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Dropouts; Randomized Controlled Trials as Topic | 2014 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States | 2014 |
[Therapy in heroin addiction].
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Buprenorphine; Euphoria; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment | 2014 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Crime; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2015 |
Therapies in early development for the treatment of opiate addiction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Design; Humans; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2015 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Opioid Use Disorders.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2016 |
Medication-Assisted Treatment of Adolescents With Opioid Use Disorders.
Topics: Adolescent; Buprenorphine; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Update on pharmacotherapy for treatment of opioid use disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2016 |
Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
Topics: Buprenorphine; Combined Modality Therapy; Education, Medical, Continuing; Health Education; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Psychotherapy | 2017 |
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2017 |
A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Drug Implants; Female; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies | 2017 |
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2017 |
Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care | 2018 |
Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; Naltrexone; Treatment Outcome | 2018 |
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Opioid Use Disorders: Perioperative Management of a Special Population.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Drug Tolerance; Humans; Interdisciplinary Communication; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Patient Discharge; Patient-Centered Care; Perioperative Care | 2018 |
Developing an opioid use disorder treatment cascade: A review of quality measures.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2018 |
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk | 2019 |
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain Management; Perioperative Care | 2018 |
CE: Acute Pain Management for People with Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Palliative Care; Substance Withdrawal Syndrome | 2018 |
Pharmacotherapy for opioid addiction in community corrections.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons | 2018 |
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2019 |
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Randomized Controlled Trials as Topic; Recidivism; Risk-Taking | 2019 |
Medication Treatment For Substance Abuse.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Patient Compliance; Patient Safety; Quality of Life; Risk Assessment; Severity of Illness Index; Substance-Related Disorders; Treatment Outcome; United States | 2019 |
Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery.
Topics: Analgesia, Patient-Controlled; Buprenorphine; Cesarean Section; Female; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain, Postoperative; Pregnancy; Pregnancy Complications | 2019 |
Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2019 |
A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Topics: Analgesics, Opioid; Buprenorphine; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Methadone; Models, Economic; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Policy; Treatment Outcome; United States | 2019 |
Consideration of opioid agonist treatment in a pregnant adolescent: A case report and literature review.
Topics: Adolescent; Ambulatory Care; Analgesics, Opioid; Buprenorphine; Child, Foster; Female; Humans; Lost to Follow-Up; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Pregnancy in Adolescence | 2020 |
Medications for management of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Medication Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Topics: Adolescent; Adolescent Behavior; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Medication-Assisted Treatment for Opioid-Use Disorder.
Topics: Algorithms; Buprenorphine; Decision Trees; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Opioid Use Disorder: Medical Treatment Options.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Evidence-Based Medicine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
Adjunctive memantine for opioid use disorder treatment: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Substance Withdrawal Syndrome | 2019 |
Medications Development for Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Drug Development; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2021 |
Buprenorphine initiation to treat opioid use disorder in emergency rooms.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
Buprenorphine: prospective novel therapy for depression and PTSD.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Prospective Studies; Stress Disorders, Post-Traumatic; Young Adult | 2020 |
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Management | 2020 |
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Topics: Adolescent; Buprenorphine; Child; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2020 |
Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
Topics: Analgesics, Opioid; Buprenorphine; Harm Reduction; Hospitalization; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2020 |
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Brain; Buprenorphine; Disease Models, Animal; Endocannabinoids; Glutamic Acid; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Orexins; Reward; Secondary Prevention; Signal Transduction; Treatment Outcome | 2020 |
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies | 2020 |
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Naltrexone; Narcotic Antagonists; Nitrosamines; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Recent Advances in the Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Implants; Humans; Injections, Intramuscular; Methadone; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Receptors, G-Protein-Coupled; Receptors, Opioid, mu; Secologanin Tryptamine Alkaloids; Thiophenes; Urea; Vaccines | 2021 |
[Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior].
Topics: Borderline Personality Disorder; Buprenorphine; Dissociative Disorders; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Observational Studies as Topic; Self Mutilation; Suicidal Ideation | 2020 |
Pharmacotherapy for Management of 'Kratom Use Disorder': A Systematic Literature Review With Survey of Experts.
Topics: Buprenorphine; Humans; Methadone; Mitragyna; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Opioid use disorder treatment for people experiencing homelessness: A scoping review.
Topics: Buprenorphine; Health Services Accessibility; Health Services Misuse; Humans; Ill-Housed Persons; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2022 |
Insights into the mechanisms underlying opioid use disorder and potential treatment strategies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Child; Cross-Sectional Studies; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; United States; Young Adult | 2021 |
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Disease Management; Drug Overdose; Female; Fentanyl; Harm Reduction; Humans; Male; Mental Disorders; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topic; Prevalence | 2022 |
Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Health Services Accessibility; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2022 |
An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Review of medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; COVID-19; COVID-19 Drug Treatment; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Naltrexone; Network Meta-Analysis; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2022 |
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Tolerance; Humans; Isoquinolines; Naltrexone; Nociceptin; Opioid Peptides; Pain; Phenylpropionates; Receptors, Opioid, mu | 2022 |
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Buprenorphine; Hospitals; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; United States | 2022 |
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Opioid Use Disorder Treatments: An Evidence Map.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2023 |
The Growing Epidemic of Opioid Use Disorder in the Elderly and Its Treatment: A Review of the Literature.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Drug-Related Side Effects and Adverse Reactions; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain, Postoperative | 2023 |
61 trial(s) available for naltrexone and buprenorphine
| Article | Year |
|---|---|
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
Topics: Adult; Blood Pressure; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1992 |
Treatment of heroin addicts using buprenorphine.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Neurologic Examination; Substance Withdrawal Syndrome | 1991 |
Opioid antagonist challenges in buprenorphine maintained patients.
Topics: Administration, Sublingual; Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Infusions, Intravenous; Male; Methadone; Naloxone; Naltrexone; Substance Withdrawal Syndrome | 1990 |
Rapid detoxification from opioid dependence.
Topics: Buprenorphine; Clinical Trials as Topic; Double-Blind Method; Humans; Naloxone; Naltrexone; Opioid-Related Disorders; Placebos; Substance Withdrawal Syndrome | 1989 |
Effects of heroin self-administration on cigarette smoking.
Topics: Adult; Buprenorphine; Heroin Dependence; Humans; Male; Naltrexone; Self Administration; Smoking; Time Factors | 1980 |
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine.
Topics: Adult; Buprenorphine; Female; Gyrus Cinguli; Humans; Male; Naltrexone; Placebos; Regional Blood Flow; Severity of Illness Index; Substance Withdrawal Syndrome; Substance-Related Disorders; Thalamus; Tomography, Emission-Computed, Single-Photon | 1994 |
Buprenorphine for benzodiazepine-abusing heroin addicts.
Topics: Administration, Sublingual; Benzodiazepines; Buprenorphine; Heroin Dependence; Humans; Methadone; Naltrexone; Substance-Related Disorders | 1994 |
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
Topics: Adult; Buprenorphine; Cocaine; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Hydromorphone; Liver; Male; Naltrexone; Narcotic Antagonists; Narcotics; Respiration; Substance-Related Disorders | 1996 |
Three methods of opioid detoxification in a primary care setting. A randomized trial.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Buprenorphine; Clonidine; Double-Blind Method; Drug Therapy, Combination; Female; Heroin; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Primary Health Care; Substance Withdrawal Syndrome | 1997 |
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.
Topics: Adult; Buprenorphine; Cross-Over Studies; Double-Blind Method; Humans; Hydromorphone; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Time Factors | 1999 |
Naltrexone shortened opioid detoxification with buprenorphine.
Topics: Adult; Analgesics; Area Under Curve; Buprenorphine; Clonidine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 1999 |
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Topics: Administration, Sublingual; Adult; Affect; Buprenorphine; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Dropouts; Psychiatric Status Rating Scales; Pupil; Receptors, Opioid, kappa; Recurrence; Substance Abuse Detection; Treatment Outcome | 2000 |
Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study.
Topics: Administration, Oral; Administration, Sublingual; Adolescent; Adult; Age Distribution; Buprenorphine; Humans; Male; Methadone; Middle Aged; Naltrexone; Socioeconomic Factors; Substance Abuse, Intravenous; Treatment Outcome | 2003 |
Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
Topics: Administration, Sublingual; Adult; Buprenorphine; Dose-Response Relationship, Drug; Humans; Male; Naltrexone; Narcotic Antagonists; Time Factors | 2003 |
Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Topics: Adult; Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2005 |
Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
Topics: Adult; Affect; Asparagine; Buprenorphine; DNA Mutational Analysis; Drug Interactions; Enzyme Inhibitors; Female; Heroin Dependence; Humans; Hypothalamo-Hypophyseal System; Male; Metyrapone; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Time Factors | 2008 |
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Buprenorphine; Counseling; Double-Blind Method; Heroin Dependence; HIV Infections; Humans; Malaysia; Naltrexone; Narcotic Antagonists; Recurrence; Risk-Taking; Treatment Outcome | 2008 |
Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
Topics: Adult; Buprenorphine; Cognition Disorders; Female; Heroin Dependence; Humans; Male; Mental Recall; Middle Aged; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Psychomotor Performance; Verbal Learning | 2009 |
Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
Topics: Adolescent; Adult; Analgesia; Analgesics, Opioid; Buprenorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Treatment Outcome | 2011 |
Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2013 |
Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia.
Topics: Acquired Immunodeficiency Syndrome; Buprenorphine; Cost-Benefit Analysis; Heroin Dependence; Humans; Malaysia; Naltrexone; Risk Factors; Risk-Taking; Treatment Outcome | 2012 |
Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cross-Over Studies; Dietary Sucrose; Double-Blind Method; England; Female; Food Preferences; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Osmolar Concentration; Sodium Chloride, Dietary; Taste Perception; Taste Threshold; Young Adult | 2013 |
A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Topics: Adult; Buprenorphine; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Topics: Adult; Buprenorphine; Craving; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Young Adult | 2014 |
Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
Topics: Adult; Behavior Therapy; Buprenorphine; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse | 2015 |
Evaluation of opioid modulation in major depressive disorder.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Cohort Studies; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2015 |
Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.
Topics: Administration, Oral; Adult; Buprenorphine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Injections; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
Baseline characteristics of patients predicting suitability for rapid naltrexone induction.
Topics: Administration, Oral; Adult; Buprenorphine; Clonidine; Delayed-Action Preparations; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Selection; Prognosis | 2015 |
Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Topics: Adult; Buprenorphine; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart; Heart Rate; Humans; Male; Moxifloxacin; Naltrexone | 2016 |
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2016 |
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Topics: Administration, Cutaneous; Adult; Arrhythmias, Cardiac; Aza Compounds; Buprenorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Pain; United States; Young Adult | 2017 |
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Combined Modality Therapy; Drug Users; Health Services Accessibility; Humans; Methadone; Mobile Applications; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Recurrence; Research Design; Smartphone; Telemedicine; Time Factors; Treatment Outcome; Wisconsin | 2016 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Remission Induction; Secondary Prevention; Young Adult | 2017 |
Effects of Buprenorphine, Methylnaltrexone, and Their Combination on Gastrointestinal Transit in Healthy New Zealand White Rabbits.
Topics: Analgesics, Opioid; Animals; Body Weight; Buprenorphine; Drug Therapy, Combination; Feces; Gastrointestinal Transit; Laboratory Animal Science; Male; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Rabbits | 2017 |
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Topics: Adult; Analgesics; Analgesics, Opioid; Buprenorphine; Clonidine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Tramadol; Treatment Outcome; Young Adult | 2017 |
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Topics: Buprenorphine; Capacity Building; Family Practice; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Organizational Innovation; Psychiatry; Research Design; Staff Development; Telemedicine; United States; Workflow | 2017 |
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Topics: Adult; Ambulatory Care; Buprenorphine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Patient Transfer; Substance Withdrawal Syndrome | 2018 |
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Outpatients; Severity of Illness Index; Substance Withdrawal Syndrome; Symptom Assessment | 2018 |
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
Topics: Adult; Buprenorphine; Comorbidity; Demography; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk-Taking; Sex Factors | 2018 |
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Topics: Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Treatment Outcome | 2020 |
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Buprenorphine; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Treatment Outcome | 2019 |
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2020 |
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Topics: Buprenorphine; Cognition; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
Topics: Adult; Buprenorphine; Clinical Protocols; Delayed-Action Preparations; Humans; Injections, Intramuscular; Jails; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2021 |
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Topics: Adult; Animals; Benzazepines; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Swine | 2021 |
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Tobacco Use | 2021 |
Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
Topics: Buprenorphine; Delayed-Action Preparations; Fentanyl; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Prescribers' satisfaction with delivering medications for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Personal Satisfaction | 2021 |
Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder.
Topics: Buprenorphine; Humans; Naltrexone; Opioid-Related Disorders; Quality of Life; Randomized Controlled Trials as Topic; Referral and Consultation | 2021 |
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine; Cocaine-Related Disorders; Delayed-Action Preparations; Enkephalins; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Protein Precursors | 2022 |
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA; Social Justice | 2022 |
Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Injections, Subcutaneous; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
282 other study(ies) available for naltrexone and buprenorphine
| Article | Year |
|---|---|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Topics: Animals; Aorta, Thoracic; Cocaine; Cyclic AMP; Electric Stimulation; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Mice; Muscle, Smooth; Opioid-Related Disorders; Rats; Receptors, Dopamine; Receptors, Opioid; Receptors, Serotonin; Substance-Related Disorders | 1998 |
The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Buprenorphine; Chlorides; Cocaine; Conditioning, Psychological; Lithium; Lithium Chloride; Male; Naltrexone; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1992 |
Discriminative stimulus properties of cocaine, alone and in combination with buprenorphine, morphine and naltrexone.
Topics: Animals; Buprenorphine; Cocaine; Dextroamphetamine; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Combinations; Male; Morphine; Naltrexone; Rats; Sodium Chloride | 1992 |
Clinical parallels of chronic drug self-administration models for treatment evaluation.
Topics: Adult; Buprenorphine; Conditioning, Operant; Heroin Dependence; Humans; Male; Models, Biological; Naltrexone; Self Administration | 1992 |
The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine.
Topics: Animals; Brain; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Methadone; Mice; Mice, Inbred Strains; Morphine; Naltrexone; Receptors, Opioid; Receptors, Opioid, mu; Seizures | 1991 |
Antagonism of acute cocaine toxicity by buprenorphine.
Topics: Analysis of Variance; Animals; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; L-Lactate Dehydrogenase; Male; Mice; Naloxone; Naltrexone | 1991 |
Effects of naltrexone on cocaine self-administration by rhesus monkey.
Topics: Animals; Buprenorphine; Cocaine; Eating; Macaca mulatta; Naltrexone; Self Administration | 1990 |
Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys.
Topics: Animals; Buprenorphine; Cocaine; Conditioning, Operant; Eating; Female; Macaca mulatta; Male; Naltrexone; Self Administration | 1990 |
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Humans; Hydromorphone; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pupil; Respiration | 1988 |
Buprenorphine has potent kappa opioid receptor antagonist activity.
Topics: Animals; Benzomorphans; Buprenorphine; Diuresis; Drug Combinations; Male; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Opioid | 1987 |
Kappa antagonist properties of buprenorphine in the shock titration procedure.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Buprenorphine; Electroshock; Fentanyl; Male; Naltrexone; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Saimiri | 1988 |
Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Buprenorphine; Columbidae; Male; Mice; Muscle Contraction; Naltrexone; Narcotic Antagonists; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Reinforcement Schedule | 1988 |
Role of opioid antagonists in treating intravenous cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Injections, Intravenous; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance-Related Disorders | 1989 |
Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzodiazepines; Buprenorphine; Cyclazocine; Ethylketocyclazocine; Fentanyl; Male; Naltrexone; Pain; Pyrrolidines; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1986 |
Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesia; Animals; Biological Assay; Buprenorphine; Butorphanol; Cyclazocine; Dose-Response Relationship, Drug; Ethylketocyclazocine; Etorphine; Fentanyl; Methadone; Mice; Morphine; Muscle Contraction; Nalbuphine; Nalorphine; Naltrexone; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, mu | 1987 |
Effects of buprenorphine on shock titration in squirrel monkeys.
Topics: Animals; Buprenorphine; Conditioning, Operant; Diprenorphine; Dose-Response Relationship, Drug; Drug Interactions; Electroshock; Male; Morphinans; Morphine; Naloxone; Naltrexone; Saimiri | 1985 |
Antagonistic and rate-suppressing effects of opioid antagonists in the pigeon.
Topics: Animals; Azocines; Benzomorphans; Buprenorphine; Columbidae; Conditioning, Operant; Diprenorphine; Dose-Response Relationship, Drug; Morphine; Naloxone; Naltrexone; Narcotic Antagonists | 1985 |
Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine.
Topics: Animals; Buprenorphine; Columbidae; Discrimination Learning; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Hydromorphone; Morphinans; Morphine; Naltrexone; Oxymorphone; Time Factors | 1984 |
Irreversible and reversible narcotic agonists: discriminative and analgesic effects of buprenorphine, oxymorphazone, and morphine.
Topics: Animals; Buprenorphine; Columbidae; Discrimination Learning; Dose-Response Relationship, Drug; Hydromorphone; Mice; Morphinans; Morphine; Naltrexone; Nociceptors; Oxymorphone | 1984 |
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.
Topics: Analgesia; Animals; Brain; Buprenorphine; Dose-Response Relationship, Drug; Male; Morphinans; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Opioid | 1981 |
Effects of opiate antagonists and putative mu- and kappa-agonists on milk intake in rat and squirrel monkey.
Topics: Animals; Buprenorphine; Cyclazocine; Diazepam; Diprenorphine; Drinking; Ethylketocyclazocine; Etorphine; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Saimiri; Taste | 1982 |
Opioid antagonists: do they have a role in treatment programs?
Topics: Buprenorphine; Drug Tolerance; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 1983 |
Clinical pharmacology of mixed agonist-antagonist drugs [proceedings].
Topics: Buprenorphine; Cyclazocine; Humans; Methadone; Morphinans; Morphine Dependence; Naltrexone | 1981 |
Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats.
Topics: Animals; Benzimidazoles; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, mu; Reinforcement, Psychology | 1993 |
In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
Topics: Analgesia; Animals; Benzomorphans; Buprenorphine; Discrimination, Psychological; Etorphine; Fentanyl; Male; Morphine; Nalbuphine; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1994 |
Naltrexone-buprenorphine interactions: effects on cocaine self-administration.
Topics: Animals; Buprenorphine; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Combinations; Eating; Female; Macaca mulatta; Male; Naltrexone; Reinforcement Schedule; Self Administration | 1993 |
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1996 |
The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1.
Topics: Animals; Bilirubin; Buprenorphine; Cell Line; Crigler-Najjar Syndrome; Glucuronates; Glucuronosyltransferase; Humans; In Vitro Techniques; Kinetics; Liver; Molecular Structure; Nalorphine; Naltrexone; Narcotics; Rats; Recombinant Proteins; Species Specificity; Substrate Specificity; Transfection; Xenobiotics | 1996 |
Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice.
Topics: Animals; Buprenorphine; Male; Mice; Mice, Inbred C57BL; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Species Specificity | 1997 |
Antagonism of morphine-like discriminative effects by beta-funaltrexamine.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Cisterna Magna; Discrimination Learning; Fentanyl; Injections; Male; Meperidine; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu | 1997 |
Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys.
Topics: Animals; Buprenorphine; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Methadone; Methadyl Acetate; Morphine; Naltrexone; Narcotic Antagonists; Narcotics | 1997 |
Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Cells, Cultured; Cyclic AMP; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Mice; Mutagenesis; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta | 1998 |
Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Animal; Body Weight; Buprenorphine; Drinking; Eating; Laparotomy; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain, Postoperative; Rats; Rats, Wistar; Specific Pathogen-Free Organisms | 1998 |
The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
Topics: Animals; Buprenorphine; Butorphanol; Columbidae; Discrimination Learning; Female; Fentanyl; Levallorphan; Methadone; Morphine; Nalbuphine; Nalorphine; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 1998 |
Effect of gonadectomy on discriminative stimulus effects of morphine in female versus male rats.
Topics: Animals; Buprenorphine; Castration; Discrimination Learning; Female; Fentanyl; Gonadal Steroid Hormones; Injections; Male; Morphine; Nalbuphine; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Rats; Rats, Sprague-Dawley; Sex Characteristics | 1999 |
Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination.
Topics: Adult; Buprenorphine; Chi-Square Distribution; Female; Hostility; Humans; Logistic Models; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Personality Inventory; Psychometrics; Severity of Illness Index; Sex Factors | 2000 |
BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Topics: Analgesics, Opioid; Animals; Benzamides; Brain; Buprenorphine; Convulsants; Electric Stimulation; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Ileum; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Naltrexone; Narcotic Antagonists; Pain Measurement; Piperazines; Radioligand Assay; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Seizures; Vas Deferens | 2000 |
[Evolution and update of detoxification techniques for opiate addicts].
Topics: Animals; Buprenorphine; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2000 |
Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.
Topics: Buprenorphine; Electrocardiography; Heroin Dependence; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Time Factors | 2001 |
Effect of opioid dependence pharmacotherapies on zidovudine disposition.
Topics: Anti-HIV Agents; Buprenorphine; Drug Interactions; Female; HIV Infections; Humans; Male; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Radioimmunoassay; Substance Abuse Detection; Time Factors; Zidovudine | 2001 |
Characterization of the discriminative stimulus effects of buprenorphine in pigeons.
Topics: Animals; Buprenorphine; Columbidae; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Tolerance; Heroin; Injections; Naltrexone; Narcotic Antagonists; Narcotics; Time Factors | 2002 |
Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Topics: Animals; beta-Endorphin; Binding, Competitive; Buprenorphine; Cell Membrane; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Female; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Male; Medulla Oblongata; Mice; Mice, Knockout; Naltrexone; Narcotic Antagonists; Narcotics; Neurons; Peptide Fragments; Pons; Radioligand Assay; Receptors, Opioid; Receptors, Opioid, mu; Rhombencephalon; Sulfur Radioisotopes; Synaptic Transmission | 2002 |
Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Topics: Alkaloids; Analgesics, Opioid; Animals; Binding, Competitive; Buprenorphine; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Etorphine; Injections, Intraventricular; Injections, Subcutaneous; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid Peptides; Pain Measurement; Peptide Fragments; Peptides; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Opioid, mu; Somatostatin | 2003 |
Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results.
Topics: Adult; Buprenorphine; Conscious Sedation; Family Practice; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Premedication; Recurrence; Substance Withdrawal Syndrome; Time Factors; Vomiting | 2003 |
Clinical treatment of opioid addiction and dependence.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Humans; Inactivation, Metabolic; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; beta-Endorphin; Buprenorphine; Disease Models, Animal; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Oligopeptides; Pain; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Time Factors | 2003 |
Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone.
Topics: Animals; Buprenorphine; Conditioning, Operant; Discrimination Learning; Female; Macaca mulatta; Male; Methadyl Acetate; Morphine; Nalbuphine; Naltrexone; Narcotics; Receptors, Opioid, mu | 2003 |
Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations.
Topics: Animals; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptin Receptor; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, kappa; Time Factors | 2004 |
Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
Topics: Adult; Buprenorphine; Emergency Medical Services; Female; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Severity of Illness Index; Substance Abuse, Intravenous; Substance Withdrawal Syndrome | 2003 |
Sex differences in opioid-induced enhancement of contact hypersensitivity.
Topics: Animals; Buprenorphine; Castration; Dermatitis, Contact; Etorphine; Female; Gonadal Steroid Hormones; Male; Morphine; Naltrexone; Rats; Rats, Inbred F344; Receptors, Opioid, mu; Sex Characteristics | 2003 |
Buprenorphine produces naltrexone reversible alterations of immune status.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Cell Division; Concanavalin A; Cytotoxicity Tests, Immunologic; Dose-Response Relationship, Drug; Interferon-gamma; Killer Cells, Natural; Male; Mitogens; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Inbred Lew; Spleen; T-Lymphocytes | 2004 |
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2004 |
Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project.
Topics: Adolescent; Adult; Ambulatory Care; Analgesics, Opioid; Anesthesia; Buprenorphine; Female; Heroin Dependence; Hospitalization; Humans; Hypnotics and Sedatives; Inactivation, Metabolic; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2005 |
Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Diprenorphine; Discrimination, Psychological; Dose-Response Relationship, Drug; Drinking; Drug Interactions; Generalization, Stimulus; Male; Meperidine; Mice; Morphine; Nalbuphine; Nalorphine; Naltrexone; Narcotic Antagonists; Saimiri; Water Deprivation | 2005 |
A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chi-Square Distribution; Cost-Benefit Analysis; Female; Heroin Dependence; Humans; Hypnotics and Sedatives; Male; Methadone; Naltrexone; Narcotic Antagonists | 2006 |
Methods of detoxification and their role in treating patients with opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Adolescent opioid abuse.
Topics: Adolescent; Adolescent Behavior; Behavior Therapy; Buprenorphine; Humans; Hydrocodone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome; United States | 2005 |
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Topics: Adult; Affect; Buprenorphine; Cocaine; Cocaine-Related Disorders; Female; Heroin Dependence; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Substance Abuse Detection; Survival Analysis | 2006 |
Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Topics: Buprenorphine; Data Collection; Drug Approval; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse Treatment Centers; Technology Transfer; United States; United States Food and Drug Administration | 2006 |
Heroin detoxification.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2006 |
Heroin detoxification.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2006 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2006 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2006 |
Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Behavior, Animal; Buprenorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Drinking Behavior; Drug Administration Routes; Drug Interactions; Eating; Ethanol; Exploratory Behavior; Male; Naltrexone; Narcotic Antagonists; Nociceptin; Nociceptin Receptor; Opioid Peptides; Rats; Receptors, Opioid; Receptors, Opioid, mu; Time Factors | 2007 |
Heroin dependence and HIV infection in Malaysia.
Topics: Adult; Buprenorphine; Demography; Female; Heroin Dependence; HIV Infections; Humans; Malaysia; Male; Naltrexone; Narcotic Antagonists; Prevalence; Risk-Taking | 2006 |
Medicalising the treatment of opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2006 |
New challenges and opportunities in managing substance abuse in Malaysia.
Topics: Buprenorphine; HIV Infections; Humans; Malaysia; Mental Health Services; Naltrexone; Narcotics; Prevalence; Registries; Risk Factors; Risk-Taking; Substance-Related Disorders | 2006 |
Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Binding, Competitive; Buprenorphine; Cells, Cultured; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Hot Temperature; Ligands; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Reinforcement Schedule | 2007 |
Regarding naltrexone for probationers and parolees.
Topics: Buprenorphine; Heroin Dependence; Humans; Injections; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Pain; Prisoners; Treatment Outcome | 2007 |
Medical treatment of opiate dependence: expanding treatment options.
Topics: Administration, Sublingual; Ambulatory Care; Buprenorphine; Drug Combinations; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Randomized Controlled Trials as Topic; Substance Abuse Detection; Treatment Outcome | 2007 |
Availability of addiction medications in private health plans.
Topics: Alcohol Deterrents; Alcoholism; Buprenorphine; Cost Sharing; Data Collection; Disulfiram; Drugs, Generic; Formularies as Topic; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2008 |
Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
Topics: Australia; Buprenorphine; Drug Prescriptions; Drug Therapy; Episode of Care; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries | 2007 |
Pharmacotherapeutic environments for substance use disorders.
Topics: Ambulatory Care; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Family Practice; Heroin Dependence; Hospitalization; Humans; Methadone; Naltrexone; Office Visits; Opioid-Related Disorders; Secondary Prevention; Substance-Related Disorders | 2007 |
Toward a rational selection of treatment for addiction.
Topics: Alleles; Buprenorphine; Genetic Variation; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2007 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline | 2008 |
Community treatment programs take up buprenorphine.
Topics: Buprenorphine; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Selection; Substance Abuse Treatment Centers | 2004 |
A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.
Topics: Buprenorphine; Drug Therapy, Combination; Female; Heroin Dependence; History, 19th Century; History, 20th Century; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Recurrence; Self-Help Groups; United States | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States | 2009 |
Substitution treatment in Malaysia.
Topics: Buprenorphine; Drug Utilization; Heroin Dependence; Humans; Malaysia; Methadone; Naltrexone; Patient Compliance; Pilot Projects; Policy Making | 2008 |
Opiate agonist treatment for addiction.
Topics: Buprenorphine; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Time Factors | 2008 |
Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.
Topics: Adult; Behavior Therapy; Buprenorphine; Epidemiologic Methods; Feasibility Studies; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prescription Drugs; Substance Abuse Detection; Time Factors | 2009 |
Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Topics: Administration, Sublingual; Adult; Australia; Buprenorphine; Drug Implants; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Substance Abuse Treatment Centers; Time Factors; Treatment Outcome | 2009 |
Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Biophysics; Brain; Brimonidine Tartrate; Buprenorphine; Dose-Response Relationship, Drug; Electric Stimulation; Enkephalin, Methionine; In Vitro Techniques; Male; Membrane Potentials; Mice; Mice, Transgenic; Naltrexone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neurons; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Yohimbine | 2009 |
Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats.
Topics: Animals; Blood Gas Analysis; Buprenorphine; Catheterization; Fentanyl; Lactic Acid; Male; Methadone; Morphine; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Narcotics; Plethysmography, Whole Body; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Respiratory Insufficiency; Respiratory Mechanics | 2009 |
Favorable mortality profile of naltrexone implants for opiate addiction.
Topics: Administration, Oral; Adult; Age Factors; Australia; Buprenorphine; Dosage Forms; Drug Implants; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Risk Factors; Sex Factors; Treatment Outcome | 2010 |
The diverse clinical uses of opioid receptor drugs.
Topics: Analgesics, Opioid; Buprenorphine; Drug Combinations; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists | 2010 |
Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
Topics: Adolescent; Adult; Buprenorphine; Delayed-Action Preparations; Drug Administration Schedule; Feasibility Studies; Female; Humans; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Parents; Patient Satisfaction; Retrospective Studies; Secondary Prevention; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2010 |
Addiction treatment in Russia.
Topics: Behavior, Addictive; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Russia; Substance Abuse, Intravenous; Suicide Prevention | 2010 |
Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Buprenorphine; Dose-Response Relationship, Drug; Drug Tolerance; Female; Levorphanol; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2011 |
Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence.
Topics: Adult; Buprenorphine; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2012 |
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Substance Abuse Treatment Centers; Substance-Related Disorders; Taurine; United States | 2011 |
Promise of extended-release naltrexone is a red herring.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Russia | 2011 |
Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide.
Topics: Buprenorphine; Cambodia; Cost of Illness; Drug Costs; Gross Domestic Product; Health Care Costs; Heroin Dependence; Humans; Laos; Malaysia; Naltrexone; Narcotic Antagonists | 2012 |
Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons.
Topics: Animals; beta-Endorphin; Buprenorphine; Calcium; Corpus Striatum; Cytosol; Fluorescent Dyes; Fura-2; Ligands; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Opioid | 2012 |
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Topics: Adult; Buprenorphine; Crime; Criminal Law; Data Collection; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pregnancy; Pregnancy Complications; Prisons; Substance-Related Disorders; Young Adult | 2012 |
A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence.
Topics: Animals; Buprenorphine; Cocaine; Cocaine-Related Disorders; Male; Naloxone; Naltrexone; Rats; Rats, Wistar; Substance Withdrawal Syndrome | 2012 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm.
Topics: Animals; Behavior, Animal; Buprenorphine; Cocaine; Conditioning, Psychological; Cues; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Reward | 2014 |
Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Treatment Outcome | 2013 |
Blocking endogenous opioids during development--do we understand the consequences?
Topics: Animals; Brain; Buprenorphine; Female; Fetal Development; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2013 |
Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
Topics: Buprenorphine; Female; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Research Design; Substance Withdrawal Syndrome | 2013 |
Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
Topics: Animals; Brain; Buprenorphine; Ethics, Medical; Female; Fetal Development; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Research Design | 2013 |
Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies.
Topics: Adult; Aging; Blood Vessels; Buprenorphine; Cross-Sectional Studies; Endothelium, Vascular; Female; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Phenotype; Pulse Wave Analysis; Regression Analysis; Vascular Stiffness | 2013 |
The clinical conundrum of perioperative pain management in patients with opioid dependence: lessons from two cases.
Topics: Adult; Buprenorphine; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain Management; Pain, Postoperative | 2013 |
Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
Topics: Alcohol Deterrents; Buprenorphine; Diffusion of Innovation; Disulfiram; Evidence-Based Medicine; Health Services Research; Humans; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Substance-Related Disorders; Surveys and Questionnaires; United States | 2014 |
Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.
Topics: Amphetamine-Related Disorders; Animals; Buprenorphine; Choice Behavior; Female; Inbreeding; Male; Methamphetamine; Mice; Morphine; Naltrexone; Narcotic Antagonists; Selection, Genetic | 2014 |
Opioid analgesics stop the development of clostridial gas gangrene.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Clostridium perfringens; Female; Gas Gangrene; Mice; Mice, Inbred BALB C; Morphine; Naltrexone | 2014 |
Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
Topics: Adult; Buprenorphine; Drug Implants; Humans; Mauritius; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2014 |
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Desipramine; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; Naltrexone; Narcotics; Nucleus Accumbens; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Swimming | 2015 |
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Research Design; Systematic Reviews as Topic | 2014 |
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Topics: Adolescent; Adult; Aged; Buprenorphine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Injections; Male; Markov Chains; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2015 |
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Male; Maze Learning; Mice; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2015 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Topics: Behavior, Addictive; Buprenorphine; Global Health; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse; United States | 2015 |
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2016 |
Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Retrospective Studies; Social Justice; United States; United States Department of Veterans Affairs; Veterans | 2016 |
Access to Addiction Pharmacotherapy in Private Health Plans.
Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Services Accessibility; Humans; Insurance, Health; Naltrexone; Substance-Related Disorders; Surveys and Questionnaires; Taurine; United States | 2016 |
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Interviews as Topic; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Preference; Substance Withdrawal Syndrome; Young Adult | 2016 |
A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Feeding and Eating Disorders; Feeding Behavior; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphinans; Naltrexone; Narcotic Antagonists; Pain Measurement; Reaction Time; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2017 |
Current Progress in Opioid Treatment.
Topics: Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2017 |
A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Topics: Adult; Australia; Buprenorphine; Drug Administration Routes; Female; Humans; Incidence; Infant, Newborn; Male; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Retrospective Studies | 2017 |
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Topics: Adult; Buprenorphine; Cohort Studies; Drug Implants; Drug Overdose; Female; Humans; Male; Methadone; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Risk Factors; Western Australia; Young Adult | 2017 |
Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder.
Topics: Adolescent; Adult; Buprenorphine; Diagnostic Tests, Routine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2017 |
Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Topics: Adolescent; Buprenorphine; Cohort Studies; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Prevalence; Retrospective Studies; United States; Young Adult | 2017 |
Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
Topics: Animals; Behavior, Animal; Buprenorphine; Cocaine; Conditioning, Operant; Cycloheptanes; Dopamine Uptake Inhibitors; Naltrexone; Narcotic Antagonists; Nociceptin Receptor; Piperidines; Rats; Receptors, Opioid; Receptors, Opioid, mu; Self Administration | 2018 |
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Topics: Adult; Age Factors; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Administration Routes; Female; Humans; Insurance Claim Review; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Practice Patterns, Physicians'; Prevalence; Sex Factors; United States | 2018 |
Screening, treatment initiation, and referral for substance use disorders.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Tobacco Use Disorder | 2017 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxyzine; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2018 |
Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
Topics: Alcoholism; Antisocial Personality Disorder; Buprenorphine; Heroin Dependence; Humans; Male; Medication Errors; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2017 |
A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non-exposed control children.
Topics: Adult; Buprenorphine; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Longitudinal Studies; Male; Methadone; Naltrexone; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; Western Australia | 2017 |
Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2018 |
State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
Topics: Adult; Buprenorphine; Government Programs; Health Policy; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; State Government; United States | 2018 |
Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Cross-Sectional Studies; Female; Humans; Injections, Intramuscular; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans; Veterans Health | 2018 |
Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Delivery of Health Care; Feasibility Studies; Female; Financing, Government; Humans; Los Angeles; Male; Middle Aged; Motivational Interviewing; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States | 2017 |
Healthcare utilization and costs associated with treatment for opioid dependence.
Topics: Adult; Age Factors; Buprenorphine; Comorbidity; Counseling; Delayed-Action Preparations; Health Expenditures; Health Resources; Humans; Male; Methadone; Middle Aged; Models, Econometric; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2018 |
A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
Topics: Buprenorphine; Delayed-Action Preparations; Facilities and Services Utilization; Female; Health Services Accessibility; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Physicians; Policy Making; Qualitative Research | 2018 |
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.
Topics: Adolescent; Adult; Buprenorphine; Cause of Death; Drug Overdose; Female; Fentanyl; Health Plan Implementation; Humans; Male; Methadone; Middle Aged; Naltrexone; Odds Ratio; Opioid-Related Disorders; Patient Discharge; Prisoners; Prisons; Retrospective Studies; Rhode Island; Transitional Care; Young Adult | 2018 |
Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Eligibility Determination; Humans; Medicaid; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2018 |
Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury.
Topics: Analgesics, Opioid; Brain Injuries, Traumatic; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Receptors, Opioid, mu | 2018 |
Injection Butorphanol dependence: A case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Butorphanol; GABA Modulators; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Nitrazepam; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Mortality; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Young Adult | 2018 |
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.
Topics: Buprenorphine; Drug Approval; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States; United States Food and Drug Administration | 2018 |
Overview of Drugs Used to Treat Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2018 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult | 2018 |
Telemedicine's Role in Addressing the Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Epidemics; Health Policy; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2018 |
In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
Topics: Animals; beta-Arrestins; Buprenorphine; Cell Line; CHO Cells; Cricetulus; Depressive Disorder, Major; Drug Combinations; GTP-Binding Proteins; HEK293 Cells; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Receptors, Opioid, mu | 2018 |
The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System.
Topics: Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Rhode Island; United States | 2018 |
Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Topics: Adolescent; Behavior Therapy; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care; Retrospective Studies; Time Factors; United States; Young Adult | 2018 |
Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.
Topics: Analgesics; Animals; Behavior, Animal; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Female; Fentanyl; Guanosine 5'-O-(3-Thiotriphosphate); Ligands; Macaca mulatta; Male; Naltrexone; Receptors, Opioid, mu; Sex Factors | 2019 |
Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.
Topics: Buprenorphine; Hospitals, Veterans; Humans; Implementation Science; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Quality Indicators, Health Care; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Citalopram; Depressive Disorder, Major; Dopamine; Drug Combinations; Drug Therapy, Combination; Male; Models, Animal; Motor Activity; Naltrexone; Rats; Rats, Inbred WKY; Serotonin; Swimming | 2019 |
Tackling addiction in primary care.
Topics: Alcoholism; Buprenorphine; Drug Combinations; Humans; Illicit Drugs; Interdisciplinary Communication; Intersectoral Collaboration; Mass Screening; Minnesota; Naloxone; Naltrexone; Opioid-Related Disorders; Prescription Drugs; Primary Health Care; Referral and Consultation; Substance-Related Disorders | 2017 |
Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
Topics: Amygdala; Animals; Behavior, Animal; Buprenorphine; Depression; Hippocampus; Male; Motor Activity; Naltrexone; Nociceptin; Opioid Peptides; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Swimming | 2019 |
Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Hospitals, Veterans; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Residential Treatment; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Nurses'; United States | 2019 |
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
Topics: Analgesics, Opioid; Buprenorphine; Diagnostic and Statistical Manual of Mental Disorders; Evidence-Based Medicine; Humans; International Classification of Diseases; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Reported Outcome Measures; Remission Induction | 2019 |
Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
Topics: Buprenorphine; Drug Overdose; Health Services Accessibility; Humans; Insurance, Health; Medicaid; Medicare; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Treatment Centers; United States | 2019 |
County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Topics: Buprenorphine; Health Services Accessibility; Humans; Logistic Models; Medicare Part D; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Residence Characteristics; Socioeconomic Factors; United States | 2019 |
Suppression of Human Natural Killer Cells by Different Classes of Opioids.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Anesthesia; Buprenorphine; Enkephalin, D-Penicillamine (2,5)-; Fentanyl; Fluoresceins; Humans; Immunosuppression Therapy; K562 Cells; Killer Cells, Natural; Loperamide; Methadone; Morphinans; Morphine; Naloxone; Naltrexone; Succinimides; Toll-Like Receptor 4; Tramadol | 2019 |
Prescription Drug and Alcohol Use Disorders: Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2019 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug Substitution; Female; Humans; Loperamide; Methadone; Methocarbamol; Muscle Relaxants, Central; Naltrexone; Narcotic Antagonists; Ondansetron; Opiate Substitution Treatment; Opioid-Related Disorders; Promethazine; Substance Withdrawal Syndrome; Sympatholytics | 2019 |
Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
Topics: Adult; Aged; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Methadone; Middle Aged; Naltrexone; Treatment Outcome | 2019 |
News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Female; Health Education; Health Information Management; Humans; Information Dissemination; Male; Mass Media; Medical Informatics; Methadone; Naltrexone; Needs Assessment; Opiate Substitution Treatment; Opioid Epidemic; Opioid-Related Disorders; Public Health; Retrospective Studies; Risk Assessment; United States | 2019 |
The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.
Topics: Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Insurance Claim Review; Male; Medicaid; Naltrexone; Narcotic Antagonists; Opioid Epidemic; Opioid-Related Disorders; Patient Protection and Affordable Care Act; Prevalence; Retrospective Studies; Risk Assessment; Survival Analysis; United States; West Virginia | 2019 |
Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
Topics: Alcohol Drinking; Animals; Azabicyclo Compounds; Buprenorphine; Dose-Response Relationship, Drug; Eating; Macaca mulatta; Male; Naltrexone; Nociceptin Receptor; Receptors, Opioid; Receptors, Opioid, mu | 2019 |
Medication-Based Treatment to Address Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Stereotyping | 2019 |
Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis.
Topics: Acetaminophen; Buprenorphine; Drug Delivery Systems; Hydrogen-Ion Concentration; Iontophoresis; Naltrexone | 2019 |
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
Topics: Adult; Buprenorphine; Cohort Studies; Delayed-Action Preparations; Drug Overdose; Female; Follow-Up Studies; Humans; Insurance, Health; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States; Young Adult | 2019 |
The case for a medication first approach to the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Certification; Health Plan Implementation; Health Services Accessibility; Humans; Methadone; Missouri; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; State Government | 2019 |
Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Topics: Adolescent; Adult; Age Factors; Buprenorphine; Drug Utilization; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; New York; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2019 |
Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Treatment Outcome | 2019 |
Use of naltrexone in treating opioid use disorder in pregnancy.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Prospective Studies; Stillbirth; Young Adult | 2020 |
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
Topics: Buprenorphine; Drug Overdose; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Retrospective Studies; United States | 2020 |
Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Young Adult | 2019 |
Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Locomotion; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley | 2019 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Drug Administration Schedule; England; Hepatitis C; HIV Infections; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Needle Sharing; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Quality Improvement; Social Work; Wales | 2019 |
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Continuity of Patient Care; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Interviews as Topic; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Satisfaction; Prisoners; Qualitative Research; Socioeconomic Factors | 2019 |
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Topics: Adolescent; Adult; Age Distribution; Analgesics, Opioid; Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time-to-Treatment; Young Adult | 2020 |
Predictors of availability of long-acting medication for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Female; Forecasting; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Surveys and Questionnaires; United States | 2019 |
Characteristics and current clinical practices of opioid treatment programs in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse Treatment Centers; Surveys and Questionnaires; Telemedicine; United States | 2019 |
Medications for opioid use disorders: clinical and pharmacological considerations.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Topics: Analgesics, Opioid; Beneficence; Buprenorphine; Correctional Facilities; Evidence-Based Practice; Health Services Accessibility; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Personal Autonomy; Prisoners; Public Health; Social Justice | 2020 |
Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Feasibility Studies; Female; Heroin Dependence; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Recurrence; Substance Withdrawal Syndrome; Young Adult | 2020 |
Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.
Topics: Animals; Buprenorphine; Dose-Response Relationship, Drug; Drug Interactions; Fentanyl; Male; Morphine; Naltrexone; Rats; Receptors, Opioid; Receptors, Opioid, mu; Reinforcement Schedule; Self Administration | 2020 |
Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Topics: Adolescent; Adult; Behavior Therapy; Buprenorphine; Decision Making; Female; Humans; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Patient Education as Topic; Prisoners; Prisons; Proportional Hazards Models; Retrospective Studies; Young Adult | 2020 |
Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Endocarditis; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Patient Discharge; Retrospective Studies; Treatment Refusal | 2020 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult | 2020 |
Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Health Services Accessibility; Humans; Medicaid; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Residential Treatment; Substance Abuse Treatment Centers; United States | 2020 |
Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Topics: Adult; Buprenorphine; Humans; Naltrexone; Opioid-Related Disorders; Perception; Pharmaceutical Preparations; United States | 2020 |
Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.
Topics: Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid Epidemic; Opioid-Related Disorders; Residential Treatment; Social Stigma; Social Support | 2020 |
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Cohort Studies; Drug Overdose; Female; Humans; Male; Maryland; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time Factors; United States; Young Adult | 2020 |
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Residential Treatment; Retrospective Studies; Substance Withdrawal Syndrome; Young Adult | 2020 |
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Topics: Buprenorphine; Cross-Sectional Studies; Female; Humans; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; United States | 2020 |
Diagnosis and Treatment of Opioid Use Disorder in 2020.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Drug and Narcotic Control; Harm Reduction; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Psychotherapy; Sensitivity and Specificity | 2020 |
Management of Opioid Misuse and Opioid Use Disorders Among Youth.
Topics: Adolescent; Adolescent Medicine; Behavior Therapy; Buprenorphine; Cause of Death; Combined Modality Therapy; Cross-Sectional Studies; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Pediatrics; Self-Help Groups; Substance Abuse, Intravenous; United States; Young Adult | 2020 |
Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Criminals; Cross-Sectional Studies; Drug Industry; Florida; Humans; Judicial Role; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Problem Solving | 2020 |
Pharmacological Properties of
Topics: Animals; Behavior, Animal; Benzamides; Buprenorphine; Drug Partial Agonism; Mice; Naltrexone; Piperazines; Receptors, Opioid, delta | 2020 |
Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Topics: Ambulatory Care Facilities; Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Health Services Accessibility; Hospitals, Veterans; Humans; Implementation Science; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Clinics; Primary Health Care; Teacher Training; United States; United States Department of Veterans Affairs; Veterans Health Services | 2020 |
Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Physicians, Primary Care; Primary Health Care; Surveys and Questionnaires; United States | 2020 |
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Behavior Therapy; Buprenorphine; Cohort Studies; Female; Health Care Costs; Hospitalization; Humans; Male; Medicare; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2020 |
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Delayed-Action Preparations; Drug and Narcotic Control; Female; Humans; Insurance Coverage; Insurance, Health; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Specialization; United States | 2020 |
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Case Managers; Counselors; Criminal Law; Criminals; Cross-Sectional Studies; Female; Florida; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2020 |
Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.
Topics: Adult; Buprenorphine; Female; Humans; Interprofessional Relations; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Care Team; United States | 2021 |
Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
Topics: Buprenorphine; Electrocardiography; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Ion Channel Gating; Methadone; Myocytes, Cardiac; Naloxone; Naltrexone; Potassium Channel Blockers; Receptors, Opioid; Time Factors | 2020 |
Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment.
Topics: Adult; Analgesics, Opioid; Bacteria; Bacteroides; Bilophila; Buprenorphine; Feces; Female; Gastrointestinal Microbiome; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Population Dynamics; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Young Adult | 2020 |
COVID-19 and treating incarcerated populations for opioid use disorder.
Topics: Buprenorphine; COVID-19; Humans; Massachusetts; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Prisons; Public Health; Telemedicine | 2021 |
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency.
Topics: Buprenorphine; COVID-19; Delayed-Action Preparations; Humans; Mobile Health Units; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2021 |
The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Health Questionnaire | 2021 |
Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020.
Topics: Analgesics, Opioid; Angiotensin Receptor Antagonists; Antidepressive Agents; Benzodiazepines; Buprenorphine; COVID-19; Drug Utilization; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Naloxone; Naltrexone; Opiate Overdose; Opioid-Related Disorders; Pandemics; SARS-CoV-2; United States | 2021 |
Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Iowa; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient-Centered Care | 2021 |
An anesthesiologist-led inpatient buprenorphine initiative.
Topics: Analgesics, Opioid; Anesthesiologists; Buprenorphine; Humans; Inpatients; Methadone; Naltrexone; Opioid-Related Disorders | 2021 |
Medication for Adolescents and Young Adults With Opioid Use Disorder.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Young Adult | 2021 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Drug Overdose; Ethanol; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Protective Factors; Wounds and Injuries; Young Adult | 2021 |
Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Family; Female; Goals; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Perception; Professional-Family Relations; Treatment Outcome | 2021 |
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Topics: Ambulatory Care; Buprenorphine; COVID-19; Health Services Accessibility; Humans; Insurance, Health, Reimbursement; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2021 |
Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Drug Monitoring; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2021 |
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
A Novel Maintenance Therapeutic for Opioid Use Disorder.
Topics: Buprenorphine; Naltrexone; Opioid-Related Disorders | 2021 |
Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Young Adult | 2021 |
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Retrospective Studies | 2022 |
Online Medication Assisted Treatment Education for Court Professionals: Need, Opportunities and Challenges.
Topics: Buprenorphine; Criminal Law; Humans; Naltrexone; Narcotic Antagonists; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice.
Topics: Buprenorphine; Cocaine; Naltrexone; Receptors, Opioid, mu | 2021 |
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Heroin; Humans; Male; Mental Health; Naltrexone; Opioid-Related Disorders; Prevalence | 2022 |
A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain | 2021 |
Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opiate Alkaloids; Opioid-Related Disorders; Prospective Studies; Retrospective Studies | 2022 |
Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2021 |
Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
Topics: Analgesics, Opioid; Buprenorphine; Health Expenditures; Humans; Naltrexone; Opioid-Related Disorders; Prescriptions; United States | 2022 |
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospital Mortality; Humans; Length of Stay; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; Prospective Studies | 2022 |
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Extended-release buprenorphine outcomes among treatment resistant veterans.
Topics: Buprenorphine; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Veterans | 2022 |
Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retention in Care; Retrospective Studies | 2022 |
Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
Topics: Aged; Buprenorphine; Cross-Sectional Studies; Dental Care; Humans; Male; Massachusetts; Medicare; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Studies as Topic; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Qualitative Research | 2022 |
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Female; Humans; Medicaid; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Quality of Life; United States; Young Adult | 2022 |
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cost Sharing; Female; Health Expenditures; Humans; Insurance, Health; Male; Medication Adherence; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2022 |
Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Topics: Adult; Analgesics, Opioid; Buprenorphine; COVID-19; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pandemics; Pharmacy; SARS-CoV-2; United States; Young Adult | 2022 |
Perioperative Management of Patients on Maintenance Medication for Addiction Treatment: The Development of an Institutional Guideline.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Understanding and co-managing medication treatment options for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Medicaid; Naltrexone; North Carolina; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
Topics: Analgesics, Opioid; Buprenorphine; Housing; Humans; Methadone; Missouri; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain; Prospective Studies | 2022 |
Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Naltrexone; Opioid-Related Disorders | 2022 |
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Cross-Sectional Studies; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Surveys and Questionnaires | 2022 |
Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
Topics: Aged; Buprenorphine; COVID-19 Drug Treatment; Cross-Sectional Studies; Ethnicity; Humans; Medicare; Minority Groups; Naltrexone; Pandemics; Prescriptions; United States | 2022 |
Gender differences among persons entering medication treatment for opioid use disorder in the community.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Sex Factors | 2022 |
The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study.
Topics: Buprenorphine; Delphi Technique; Evidence-Based Medicine; HIV Infections; Humans; Naltrexone; Substance-Related Disorders; United States | 2022 |
Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.
Topics: Analgesics, Opioid; Buprenorphine; Bupropion; Central Nervous System Stimulants; Cross-Over Studies; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Humans; Medicaid; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Infant, Newborn; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Retrospective Studies | 2022 |
Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
Topics: Actigraphy; Analgesics, Opioid; Animals; Buprenorphine; Humans; Macaca mulatta; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Sleep | 2022 |
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care; Retrospective Studies | 2022 |
Use of long-acting injectable buprenorphine in the correctional setting.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisons; Retrospective Studies | 2022 |
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Physician Assistants | 2022 |
Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Treatment Outcome | 2022 |
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Topics: Aged; Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Female; Humans; Longitudinal Studies; Male; Medicare; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics; Telemedicine; United States | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Humans; Medicaid; Methadone; Naltrexone; Opioid-Related Disorders; Primary Health Care; United States | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Depression; Humans; Naltrexone; Opioid-Related Disorders | 2023 |
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.
Topics: Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Social ecological factors and medication treatment for opioid use disorder among justice-involved rural and urban persons: the
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Overdose; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Observational Studies as Topic; Opioid-Related Disorders; Recurrence; Reproducibility of Results | 2023 |
Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine.
Topics: Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Massachusetts; Naltrexone; Opioid-Related Disorders | 2023 |
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Augmenting project ECHO for opioid use disorder with data-informed quality improvement.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Surveys and Questionnaires | 2023 |
In brief: Over-the-counter Narcan nasal spray.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Nasal Sprays; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Topics: Aged; Analgesics, Opioid; Benzodiazepines; Black or African American; Buprenorphine; Healthcare Disparities; Hispanic or Latino; Humans; Medicare; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Overdose; Opioid-Related Disorders; United States; White | 2023 |
Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Diphenoxylate; Humans; Loperamide; Methadone; Naltrexone; Nonprescription Drugs | 2023 |
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder.
Topics: Ambulatory Care; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care | 2023 |
Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Topics: Buprenorphine; Humans; Long QT Syndrome; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Retrospective Studies; United States | 2023 |
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Female; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2023 |
Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
Topics: Addiction Medicine; Adult; Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; United States | 2024 |
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Female; Humans; Leadership; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2023 |